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1 Introduction  
1.1 Relevance and Motivation 
 
Dental care within the context of the German health care system differs from other 
types of medical care due to the high proportion of cost sharing by patients. Many state-
of-the-art dental treatments require high private cost contributions from patients (KZBV 
2018), but close to 90% of the patient population have serious doubts about the ben-
efits of additional medical services offered to them (Klemperer and Dierks 2011). Hence, 
there is a strong imperative for transparent communication of the value for money of 
care that is provided to patients (Klingenberger et al. 2006). Beyond the actual call for 
cost sharing, today’s dental care decision making increasingly requires knowledge 
sharing and demands shared decision making (Frosch and Kaplan 1999). Hence there 
is a strong need for dentists to provide patient-centered advice (Johnsson and Nordgren 
2019) and highly personalized information about the benefits of treatment options to 
patients (Elwyn et al. 2010). The dentist´s role as an advisor is becoming increasingly 
important beyond the sole role of providing high-grade technical services to patients in 
clinical processes. Education and counseling of patients as well as informing and ex-
plaining proposed diagnostic and therapeutic measures takes up an increasingly large 
portion of the daily work routine (Klingenberger et al. 2006).  
However, several challenges exist in daily clinical practice that may have an impact 
on the implementation of the latter requirements into today´s clinical decision mak-
ing. 
What is special about dental care decision making and why may it be difficult for 
dentists to transparently communicate value for money to patients? The economic 
concept of asymmetric information (Hillier 1997) is highly applicable to the dental 
health decision making context. In clinical practice, dentists advise patients on which 
therapeutic option to choose, since dentists have significantly higher knowledge of treat-
ment options and corresponding health outcomes (Darbar 2018). The knowledge gap 
between dentists and patients can create a significant imbalance of power, which makes 
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it difficult for patients to assess the appropriateness of recommended treatment op-
tions (Arrow 1963). It needs to be considered that within this asymmetric information 
constellation dentists may have an income interest since they earn money from executing 
the recommended treatments. The risk of supplier-induced demand is inherent to dental 
care decision making scenarios (Birch and Listl 2015). This raises the serious question 
of the extent to which dentists consider only patients’ preferences for value for 
money when giving advice to patients on which treatment option to choose. As a 
result, unbiased evidence about the value for money of recommended treatment op-
tions is needed for clinical decision making in dental care.  
Why may it be difficult for dentists to provide personalized health care recommen-
dations to patients? There are several challenges making it difficult for dentists to pro-
vide personalized healthcare recommendations to patients. Historically, providing per-
sonalized information to patients may have been an underdeveloped area. The classic 
social model of the dentist-patient relationship (Sondell and Soderfeldt 1997), under 
which dentists only provide little information about planned treatment and under which 
patients blindly follow dentists’ advice, is no longer valid (Klingenberger et al. 2006). 
Today’s preferred model is characterized by mutual coherence and participation in the 
decision process (Reissmann et al. 2019) and by mutual agreement on therapeutic op-
tion choices (Scheibler and Pfaff 2004). This raises the question of how patients’ pref-
erences can be accounted for and how therapies can be tailored around patients’ 
needs. In many cases, patients’ preferences in clinical practice are limited due to 
budget restrictions (Varian 2003). Therefore, dentists must be able to advise which 
options to choose in a limited resources scenario. Dealing with decision making under 
budgetary constraints of patients is becoming a crucial pillar in todays’ clinical prac-
tice. However, evidence for decision making under budgetary constraints is limited 
and not readily available in all fields of dentistry (Shariati et al. 2013). 
How can health economics contribute to addressing the challenges, i.e. establishing 
evidence for the transparent communication of the value for money and enabling 
shared decision-making support to patients under budgetary constraints?  
Health economics is the discipline applying economic toolkits to health care scenarios 
(Arrow 1963) and economic evaluation (EE) is a concept that is used when choices need 
to be made between different alternatives (see section 2.1). EE can be applied to the 
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oral health context in order to identify, to measure and to value the inputs and outputs 
of alternative options (i.e. therapeutic options), thereby enabling a comparative anal-
ysis of one or more treatment alternatives with the goal of maximizing the health 
output under a given budget (Drummond 2001). There are several benefits resulting 
from applying EE techniques to the dental care setting. When EE is applied to daily 
clinical decision making contexts, the analysis can reveal the real value of treatment 
options for the money without risk of supplier-induced demand (Birch and Listl 
2015). Furthermore, EE can simulate decision making under consideration of budget-
ary constraints, even though budget restrictions might be a priori unknown (Elhanan 
1988). Hence, EE can be considered as enabler of evidence-based and patient-centered 
decision making in the dental care context. 
The motivation of this dissertation is to explore the extent to which existing health 
economic frameworks can be applied to the oral health context and to assess how the 
application can help dentists and patients to better choose from therapeutic options. 
This dissertation aspires to show the limitations of daily clinical decision making and 
attempts to demonstrate how EE can be applied to overcome these limitations. More-
over, beyond the technical economic analysis, this dissertation aspires to give an outlook 
on what impact EE can have beyond the micro-economic level. It will be discussed to 
what extent EE can contribute to total welfare improvements and to real world change 
(i.e. by creating awareness that might ultimately induce willingness of dentists to em-
brace new treatment approaches). Since evidence in health economics for dentistry has 
been a neglected concern (Shariati et al. 2013), especially within the German context 
(Kirch 2008), this dissertation claims to be the first comprehensive health economic 
contribution in the field of endodontics. 
Bringing it all together, EE can help to make better use of resources in the context of 
oral disease management, which is the key motivation of this dissertation, with the 
latest evidence suggesting that up to 34% of expenditures in health care are wasted or 
allocated towards inappropriate health care decisions (OECD 2017).  
Since the focus of this dissertation from a dental medical perspective is on endodontics, 
this area of dentistry will be introduced in the next section first. 
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1.2 Endodontics – Pulpal Disease Management 
 
Endodontics is a field within conservative dentistry that deals with the anatomy and 
physiology of the pulp as well as with the diagnosis, treatment and prevention of pa-
thologies of the dental pulp and surrounding tissues (Weber 2017). The pulp is defined 
as the soft tissue inside the tooth that contains nerves, vessels and lymphatic tissue 
(Hargreaves and Louis H. Berman 2015). 
Pathologic conditions of the pulp can occur when bacteria enter the pulp and cause an 
inflammation that can ultimately lead to tissue death, which is associated with a tooth 
becoming de-vital, or even cause an inflammation of the tissue surrounding the root ends 
of a tooth. There are different ways in which bacteria enter the pulp, but most infections 
occur as a result of the dental pulp having been exposed, e.g. by deep carious lesions or 
trauma (Sivapathasundharam 2016). An overview of different pathologic endodontic 
conditions and possible treatments can be depicted as follows: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Avulsed 
Tooth 
 
1) Open 
Pulp 
2) Cracked 
Tooth 
 
1) Cavity 
2) Inflamed  
Pulp 
3) Inflamed 
Root End/ 
Apical Ab-
scess 
 
4) Filling 
5) Pulp Capping 
6) Root Canal Fil-
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Figure 1: Overview of Pathologic Endodontological Conditions and Treatments (Own - 
Derived from (Weber 2017) p.71) 
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Endodontic treatments (Hargreaves and Louis H. Berman 2015) can be mainly catego-
rized into preventive endodontics (e.g.  protection of the pulp), conservative endodon-
tics (e.g. root canal treatment and re-treatment in case of failed first line root canal treat-
ment), endodontic surgery (e.g. root-end surgery) and trauma treatment (e.g. treatment 
of a cracked tooth). 
Different therapeutic treatment options exist that can be applied to prevent or elimi-
nate an inflammation of the root canal system and result in a positive long-term prog-
nosis for a tooth to remain in the mouth as an alternative to ultima ratio treatment, i.e. 
extraction. These include: 
 
 Treatment of pulpal discomfort (e.g. pain hypersensitivity treatment – see 
chapter 3) 
 Pulp capping (applying a “patch” to a small pulp opening in certain cases – see 
chapter 4),  
 Root canal treatment (removal of pulpal tissue after irreversible infection, dis-
infection of the root canal system and obturation – see chapter 4) 
 Root canal re-treatment (re-treatment of failed first-line root canal treatment – 
see chapter 4) 
 Root end surgery (surgical removal of an inflamed root end after root canal 
treatment) 
 Treatment of trauma (e.g. re-plantation of a tooth that has been out of the 
pocket – see chapter 5) 
 
Even though clinical research in endodontics has experienced strong growth, especially 
over the last decade (Naik et al. 2016), the latest clinical evidence has not yet fully 
translated into the German public health care system (KometDental 2018). Compared 
with other fields of conservative dentistry, endodontics still requires very high cost 
contributions from patients since reimbursement regulations for endodontic treat-
ments are very restricted (KZBV 2018). Decision scenarios in endodontics are highly 
applicable for health economic research due to the vast availability of therapeutic al-
ternatives and due to considerable cost differences and cost contributions involved for 
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patients. For defining the scope of this dissertation, several scenarios will be introduced 
in the next section. 
1.3 Clinical Scenarios for this Dissertation 
 
Three distinct, relevant and clinically meaningful decision making scenarios in en-
dodontics are addressed in this dissertation. The aim here is that these clinical scenarios 
cover all major treatment categories presented in the previous section to ensure a broad-
based health economics analysis for the field of endodontics: 
 
1. Pain Scenario: a patient is visiting the dentist’s office due to a painful tooth when 
drinking or eating. In many cases, pain is related to dentin-hypersensitivity of a 
tooth, which can be treated by administration of pain-reducing agents. However, 
there are many different agents that can be applied to a sensitive tooth. Some 
treatment options are covered by public health insurance, some treatments require 
co-pay (Lin et al. 2013). The question is then which agent should be applied and 
under which conditions it makes sense to invest in more expensive treatments 
for pain reduction? For further details see Chapter 3.  
 
2. Open Pulp Scenario: when a dentist is treating a deep carious lesion of a tooth, 
the pulp can be opened, which requires follow-up treatment. One first-line treat-
ment option is treating a tooth with pulp capping (Mente et al. 2014), for which 
different materials can be used (CaOH or MTA). However, MTA requires co-pay 
from a patient. Evidence is needed to determine under which conditions it makes 
sense to invest in MTA as a material for pulp capping. Since both agents have 
failure rates, cost and clinical effectiveness of follow-up treatment need to be 
taken into account. The question is then if and under which conditions does it 
makes sense to invest in MTA as more expensive material in case of an open 
pulp? For further details see Chapter 4. 
 
3. Trauma Scenario: a patient is visiting the dentist’s office due to an avulsed tooth 
(tooth out of pocket) caused by trauma. If the tooth has not been out of the pocket 
for a long time and has been stored properly, a dentist can recommend replantation 
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of an avulsed tooth (Andreasen et al. 1995). However, the cost of replantation is 
high and there is a risk of failure. Clinical data is very limited for success rates of 
replantation of an avulsed tooth and evidence-based decision making is only con-
ditionally possible. The question is then under which conditions does it makes 
sense to invest resources into re-planting a tooth? A priori it is not clear if a 
robust model can be built upon the rudimentary clinical data available. The 
goal is to assess decision uncertainty within the model. For further details see 
Chapter 5. 
 
All together, it can be stated that with 9 million hypersensitivity treatments, 7 million 
root canal treatments and 0.8 million pulp capping treatments performed in Germany 
each year (see section 3.2 and section 4.2), all these scenarios are highly relevant clinical 
scenarios for general dental practitioners as well as for dentists specialized in endo-
dontics.  
1.4 Research Questions  
 
Based on the clinical scenarios, three distinct and concise research questions were for-
mulated, which will provide guidance for the three main chapter of this dissertation and 
will be profoundly explored and discussed: 
 
1. Which of the currently available treatment options for dentin hypersensitiv-
ity is the most cost-effective? The hypothesis is that there might be treatment 
alternatives that are more cost-effective than the gold standard treatment (chemi-
cal occlusion). 
2. There is evidence that MTA has a high clinical effectiveness when treating an 
open pulp. However, MTA is also more expensive than CaOH and treatment 
alternatives outside of pulp capping exist. The question arises which treatment 
option is cost-effective in the long run when cost and effectiveness of follow-up 
treatments are considered. The hypothesis is that the application of transition 
state modeling enables long-term decision making.  
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3. Is replantation of an avulsed tooth a cost-effective treatment alternative in 
case of dental trauma, or are other therapeutic alternatives more cost-effective? 
The hypothesis is that a robust model can be built from the limited clinical data 
available and that variance analysis can be applied to assess the uncertainty of 
decision making within the model. 
 
The goal of this dissertation is to identify the most cost-effective therapeutic alterna-
tives for the given scenarios by modeling clinical decision situations based on 1) cur-
rently available clinical evidence for the effectiveness of treatments of teeth and the per-
iodontal system in case of pulpal disease treatment, and 2) available cost information 
within the context of the public and private German health care system. 
Since there are various approaches available that can be used to identify cost-effective 
therapeutic alternatives in endodontics, the next chapter will focus on assessing available 
methodologies in health economics and will provide details about the methodical ap-
proach for this dissertation. 
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2 Methodology  
2.1 Background 
 
Three main types of EE analysis in health economics can be differentiated. Cost Effec-
tiveness Analysis (CEA), Cost-Utility Analysis (CUA) and Cost-Benefit Analysis 
(CBA) are established tools for modeling. With these tools, cost and health outcomes for 
two or more treatment alternatives can be weighed up and evidence-based recommenda-
tions for therapeutic alternatives can be derived (Drummond 2001). The suitability of 
each tool for the given scenarios in this dissertation will be assessed in the following 
sections. 
2.1.1 Cost Effectiveness Analysis (CEA) 
CEA was first introduced in 1977 by Weinstein (Weinstein and Stason 1977). CEA is an 
evaluation technique in which the clinical outcome of a treatment (effectiveness) and the 
resources used for treatment (cost) for different treatment alternatives are analyzed com-
paratively by calculating the cost per non-monetary outcome measure for each available 
alternative: 
 
Cost Effectiveness (of Alternative) =
Cost (of Alternative)
Effectiveness (of Alternative)
 
 
In CEA, cost is measured in monetary units. Effectiveness is measured in non-monetary 
units, e.g. life-years gained, pain-free years/days, number of post-treatment complica-
tions, patient satisfaction, etc.  
After cost and effectiveness of different alternatives have been calculated, rules are de-
scribed for decisions making based on the relation between the two numbers (Robinson 
1993). For instance, when Cost of Alternative 1 < Cost of Alternative 2 and Effectiveness 
of Alternative 1 > Effectiveness of Alternative 2, it is easy to reject Alternative 2. 
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In economics, marginal considerations always play an important role and economists pre-
fer to analyze the extra cost that is needed to gain an increment of effectiveness Therefore, 
the concept of incremental cost-effectiveness ratios (ICER) is introduced for CEA: 
 
 
Incremental Cost Effectiveness Ratio    
=
Cost of Alternative −  Cost of Alternative
Effectiveness of Alternative −  Effectiveness  of Alternative
 
 
 
ICERs allow analysts to make statements about the incremental cost of one additional 
unit of health whenever two therapeutic alternatives are compared (Pearson 2018). 
2.1.2 Cost-Utility Analysis (CUA) 
Cost-utility analysis (CUA) is a derivate of CEA that includes the time factor and the 
utility. The first CUA was published in 1968 (Klarman 1968) on renal disease. CUA 
became the technique of choice when overall health of a patient is assessed. It is meas-
ured in Quality Adjusted Life Years (QUALY). A QUALY is a “life year gained” multi-
plied by the “utility ratio” (number ranging from 0=death to 1=perfect health). For exam-
ple: If a patient is about to die without treatment within one year at 20% of perfect health, 
his QALY is 0.2*1=0.2 QUALY. If a treatment allows him to live 5 more years at 60% 
of perfect health, his QUALY with treatment would be 5*0.6=3.0 QUALYs and his net 
gain for the treatment would be 2.8 QUALYs (Zweifel 2013). 
2.1.3 Cost-Benefit Analysis (CBA) 
CBA was first used in health care in 1962 (Roberts 1962). CBA differs from CEA in that 
monetary units are assigned to both cost and clinical effectiveness. It may be the case 
that a common unit of measurement is needed for different alternatives, and since money 
is a very convenient and common unit it is used in CBA for measuring clinical effective-
ness. In order to compare alternatives, the benefit-cost ratio is calculated for each alter-
native.  
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Cost Benefit Ratio   =
Benefit (of an Alternative)
Cost (of an Alternative)
 
 
Using monetary measures as a vehicle makes it also possible to integrate qualitative and 
quantitative measures into a common summary, the cost-benefit ratio. The cost-benefit 
ratio can be calculated for every single alternative and indicates whether the costs out-
weigh the benefits. A widely accepted advantage of CBA is that the unit of analysis (mon-
etary units) can be easily and universally understood by decision makers (Leung 2016).   
2.2 Applied Methodology of this Dissertation 
 
Historically, methodology choice has been a matter of dispute in EE and the analyses 
at hand have various pros and cons that are evaluated for this dissertation at this point 
(Drummond et al. 1993).   
CBA has the advantages of providing a common monetary denominator of inputs and 
outputs, but there are several challenges inherent in the use of this EE tool in the 
healthcare context. While various approaches exist for the valuation of health benefits 
in monetary measures (e.g. contingent valuation method (Olsen and Donaldson 1998), 
discrete choice experiments (Ryan 2004) or conjoint analysis (Ryan and Farrar 2000)), 
there are several reasons given in the literature for why monetary measures of health 
benefits are difficult to assess in medical and dental care. It is argued that it is prob-
lematic for an individual to attach value to health (Drummond 2001), while there is also 
controversy around the idea of placing a monetary value on human life (Card and 
Mooney 1977). Furthermore, preference revelation is problematic when health is partly 
financed indirectly through a health care system and therefore patients do not necessarily 
reveal their valuation of benefits in health markets (Watson and Ryan 2007). As of today, 
comparable and reliable monetary values are not available for dental health benefits 
as required by the decision making contexts of this dissertation. Therefore, CBA is not 
applied in this dissertation. 
As for CUA, transferring this concept to dental health economics means that the impact 
of oral diseases, treatments and the corresponding clinical effectiveness need to be 
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translated into a QUALY (Kay et al. 2018). However, since oral diseases (except e.g. oral 
cancer) have only a marginal effect on the utility ratio and the overall expected lifetime 
of a patient, QUALY data as needed for endodontics is as of today not available. An 
alternative approach to QUALY is to measure “dental utility” analogously to QUALY 
“life utility”, resulting in a Quality Adjusted Tooth life measure – QUATY. However, 
endodontic treatment QUATYs have not yet been derived (Mohd-Dom 2014). Therefore, 
CUA is not applied in this dissertation. 
There are various reasons why CEA is the methodology of choice for this disserta-
tion. The fact that underlying clinical studies provide measures of clinical effectiveness 
that can directly be used and extended into required cost-effectiveness makes CEA 
highly applicable and a very pragmatic approach in the context of this dissertation. 
Also, CEA is suitable for research where costing and budgeting is important – and 
this is the case as demonstrated in the scenario description and research question. There-
fore, CEA allows to focus on the key question of this dissertation, to evaluate decision 
making under budgetary restraints and to highlight the use of scarce resources 
(Drummond 2001). However, it needs to be admitted at this point that there might be 
several limitations inherent to CEA that place limitations on the model and on this dis-
sertation itself. Details concerning the limitations of CEA within the context of this dis-
sertation will be explored in the discussion part (see section 6.2) 
After the methodical choice in favor of CEA has been made for this dissertation, the last 
section of this chapter will deal with CEA modeling required to explore the research 
questions and the process that will be followed to implement endodontic health care de-
cision models. 
2.3 CEA Modeling and Applied Modeling Process  
 
The CEA analysis of this dissertation will be performed by using the software TreeAge 
Pro 2019 (TreeageSoftware 2019), which offers a model building tool and various 
analysis tools as well as extended functionalities (i.e. variance analysis functions) de-
signed for the implementation of CEA in health care. The software will be used to build 
decision trees, which are mathematical structures that include decision nodes, health 
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states and extended logic and can be used to represent and simulate the health and cost 
outcomes for a tooth or population for the given scenarios (Myles et al. 2004). 
The decision trees of each model are enriched with available clinical data from the field 
of dental medicine, for which a systematic literature research is performed to identify 
highest available evidence levels for the different scenarios; i.e. a secondary use of pub-
lished clinical data is performed. To enrich the models with cost data, the cost of different 
alternatives is assessed and calculated according to BEMA (Einheitlicher Bewertung-
smaßstab für zahnärztliche Leistungen (uniform fee scale for dental interventions)) and 
GOZ (Gebührenordnung für Zahnärzte (fee scale for dentists)) within the context of the 
German health care system. Health states are included with the introduction of Markov 
Models (Cassidy et al. 2019) and Monte-Carlo Simulations (Di Paola et al. 2018) are 
used to populate the models. The data emerging from the different models will reveal 
information about the cost effectiveness ratios of different therapeutic alternatives. Risk 
will be incorporated and analyzed under sensitivity analysis. A basic concept and process 
that the CEA models will follow in this dissertation can be depicted as follows: 
 
 
 
 
 
 
Figure 2: Modeling Process of CEA in this Dissertation (Own – Derived from (Quade 
1970), p.236) 
Each research question requires its own case-specific model. Therefore, three different 
models will be built, which will result in three main chapters forming the main part of 
this dissertation (chapters 3-5). 
Relevant Alternatives 
A3 
   A5 
A2 
   A4 
A1 
Model 
(reflection of  
reality) 
A1 
A2 
A3 
A4 
A5 
Preferred Alternatives 
Cost 
Effectiveness 
Logic 
(assessment 
and ranking of 
alternatives) 
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3 Deciding on the Cost Effectiveness of Therapeutic 
Alternatives for the Treatment of Algesic Irritation 
of the Pulp (Dentin Hypersensitivity) 
 
3.1 Background 
 
According to the latest available data from the German Federal Union of Public Dentists 
(KZVB), treatment for hyper-sensitive teeth within the public German healthcare context 
occurred 9,346,500 times in 2013 (KZBV 2014). Assuming 302 working days in 2013, a 
decision in favor of dentin hypersensitivity treatment was made 30,949 times every 
working day – only taking into account public dentists. Looking at the data from a dif-
ferent angle, out of 100 cases reported to KZBV in which conservative or surgical treat-
ment was needed, 10.2 cases (i.e. 10.2%) included dentin hypersensitivity (DHS) 
treatment. Given that 50,264 public dentists were registered in 2014, the conclusion can 
be drawn that – on average – every single public dentist decided for, performed and 
accounted for DHS treatment every second working day. 
The numbers above make it quite obvious that most dentists clearly decide to treat the 
condition of DHS, and it has become a very common standard treatment in Germany’s 
healthcare system. However, the best way to treat the condition is still a matter of 
dispute from a health economics perspective. There are various ways to treat this con-
dition. Considering the absolute numbers of treatments performed per year in Germany, 
the need for a health economics analysis is readily apparent. 
3.2 Dentin Hypersensitivity (DHS) from a Medical Perspective 
 
Before delving into the effects of how to treat DHS, this dissertation will convey a deeper 
appreciation of the medical science behind DHS. The question that will be addressed is 
how DHS is defined from a medical perspective and what conditions and processes that 
cause this pathologic condition are. 
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3.2.1 DHS Definition and Overview 
The definition of DHS is as follows:  
“A short sharp pain arising from exposed tubuli in response to various stimuli … 
which cannot be ascribed to any other form of dental defect or pathology”(Holland 
et al. 1997). 
Stimuli causing pain range from thermal, electrical, mechanical (tactile), osmotic and 
evaporation to chemical stimuli. The thermal stimulus (cold) is most common among 
patients (Shiau 2012). Not every patient suffering from DHS will seek in-office treatment, 
since the pain presentation may only be in the range of a minor inconvenience. But 
patients may also end up with quality-of-life disturbing pain (Hellwig et al. 2009).  
It is important to be clear about the differential diagnosis of DHS. Before a diagnosis of 
DHS can be made, other defects and pathologies must have been ruled out. Normally, 
this is done by asking the patient for pain quality and duration. Pain caused by DHS 
normally lasts as long as the stimulus. Other pain-causing defects or pathologies (e.g. 
cracked tooth syndrome, pulp infection, and pulpal sensitivity) normally feature a differ-
ent pain presentation. For instance, pulp infection features a long-lasting pain and exag-
gerated response to a stimulus (Chen and Abbott 2009). The focus here is strictly limited 
to DHS, and other pain-causing dental conditions are not considered.  
3.2.2 Macro- and Micro-Anatomy of DHS 
It is important to understand what causes the discomfort or even pain when speaking 
about DHS and what the medical preconditions that may lead to DHS are. An analysis of 
the tooth anatomy and physiological processes behind DHS is therefore provided here. 
 
Macro-anatomy: DHS can only occur when the dentine surface is exposed and den-
tinal tubules are open (Addy et al. 2000). This is the case e.g. when 
gingival recession occurs, cementum is abraded, enamel is attrite, 
or an erosion is persistent. Therefore, DHS can only persist with a 
pre-existing pathology. 
Micro-anatomy: Dentin is characterized by having tubules which reach from the den-
tin-enamel junction to the pulp. Tubules are filled with a serum-like 
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fluid and odontoblast cells, which are located in the pulp chamber. 
Odontoblasts, in turn, are accompanied by or connected with nerve-
endings of neurons, which, when polarized, send signals to the brain. 
In other words, dentin has tiny “pores”, which connect the tooth’s sur-
face with the pulp. Through this connection, a stimulus can be con-
ducted from the pathologic tooth surface to the pulp, and stimulation 
of the pulp is mostly related to pain.   
Physiology: There are currently three main theories in the literature to explain the 
physiology of DHS and how a stimulus is conducted (Garg and Garg 
2010): 
 Neural theory: Nerve fibers in the dentine tubule are directly ex-
cited by a stimulus and afferent neurons forward the stimulus to 
the brain, resulting in pain.  
 Odontoblastic transduction theory: Odontoblasts receive the 
stimulus and transmit the stimulus to sensory nerve endings via a 
synapse.  
 Hydrodynamic fluid shift theory (Brannestrom 1963): Fluids in 
the dentin tubule are deviated inbound and outbound and the fluid 
shift stimulates nerve endings in the pulp. 
The hydrodynamic fluid shift theory is the most widely accepted. 
However, there is as yet no final agreement on the mechanisms to fully 
elucidate DHS (Lin et al. 2013).  
3.2.3 Epidemiology 
A systematic review by Splieth (Splieth and Tachou 2013) on the prevalence of DHS 
revealed that reliable longitudinal studies hardly exist. The prevalence in existing studies 
ranges from 3% to 98% in adults, whereas most studies conclude that the prevalence 
ranges from 3 to 57%, depending on the study sample. However, there are many reasons 
why existing studies are not representative (e.g. selection bias, diagnostic criteria, etc.). 
Therefore, Splieth and Tachou estimated that the life-time prevalence is supposedly 100% 
and 1-3 month prevalence “will range from 10 – 30% in adults with very little variation 
for gender or age in a population sample” (Garg and Garg 2010).  
17 
 
3.2.4 Treatment Alternatives (Strategies) and Desensitizing Agents 
There are various options for the treatment of DHS, but being aware of the fact that 
the pre-conditions for DHS are exposed and open tubules, the main strategy behind treat-
ment quickly becomes clear – occlusion of open tubules: 
 Physical occlusion of the dentin tubule to prevent the flow of fluids 
 Chemical occlusion of the dentin tubule to prevent the flow of fluids 
Furthermore, interruption of stimuli is also a legitimate option: 
 Nerve desensitization with potassium nitrate 
 Laser treatment 
The table below shows that different treatment “agents” are available for every category 
mentioned above. 
 
 
      Figure 3: DHS Treatment Options and Agents (Lin et al. 2013) 
 
At this point, it may be noted that the table above does not include treatment agents like 
desensitizing toothpastes or desensitizing mouth wash and the like. This is because this 
dissertation is limited to in-office treatment alternatives and agents, and toothpastes 
etc. are non-prescription home-care products and therefore are not considered in this 
model. But it is highly recommended to apply home-use desensitizing agents in case of 
light DHS as a first step before looking for in-office treatment (Garg and Garg 2010). 
Treatment Strategy: Physical Occlusion Chemical Occlusion Nerve Desensitization Laser Therapy
Treatment Agents: Pumice Paste Fluorides** Potassium nitrates (NK) XGY:Laser
Sodium Bicarbonate Oxalates Guanethidine
Hydroxyapatites Glutaraldehyde Agents
Bioglasses Calcium compounds
Glassionomers
Dentin Bonding Agents*
Resin Adhaesive*
* Mostly used in this category ** Brand e.g. Duraphat
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3.3 Health Outcomes and Clinical Effectiveness of DHS 
Treatment 
3.3.1 Underlying Meta-Analysis for CEA Modeling 
For an economic evaluation model in DHS treatment, recent and reliable data on clinical 
effectiveness is needed. Systematic review of the literature was conducted, using the Pub-
Med-Database. The Query „Dentin Hypersensitivity“ & „Meta Analysis“ (01.11.2018) 
specified a result-set of 5 publications from within the last 10 years. Search Criteria were: 
 ("dentin sensitivity"[MeSH Terms] OR ("dentin"[All Fields] AND "sensitiv-
ity"[All Fields]) OR "dentin sensitivity"[All Fields] OR ("dentin"[All Fields] 
AND "hypersensitivity"[All Fields]) OR "dentin hypersensitivity"[All Fields]) 
AND (Meta-Analysis[ptyp] AND "2005/01/11"[PDat] : "2014/01/11"[PDat]) 
Out of the 5 Meta-analyses, 4 publication were excluded according to the following 
reasons: 
 (Sgolastra et al. 2013) was restricted to laser treatment  
 (De Munck et al. 2012) was restricted to dentin bonding 
 (Cunha-Cruz et al. 2011) was restricted to oxalates 
 (Poulsen et al. 2006) was restricted to potassium 
The data for clinical effectiveness of DHS treatment is taken from: 
 
Lin, et al (2013): In-office treatment for dentin hypersensitivity: a systematic re-
view and network meta-analysis 
 
It was found that Lin´s meta-analysis comprises all treatment options that can be chosen 
by dental health decision makers as of today for the treatment of DHS. Furthermore, an 
evaluation of the meta-analysis using the PRISMA Checklist (PRISMA 2015) was posi-
tive, thus ensuring the transparency and completeness of the meta-analysis at hand. 
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3.3.2 Clinical Parameters used for CEA Modeling 
The clinical effects in Lin’s network meta-analysis that will be used for decision modeling 
are shown below: 
 
Clinical Effect (95% CI)
SMD Pain Scale Reduction
Physical Occlusion vs. Placebo Treatment -2,57 (-4,24 ; -0,94)
Chemical Occlusion vs. Placebo Treatment -2,33 (-3,65 ; -1,04)
Nerve Desensitization vs. Placebo Treatment -1,72 (-4,0 ; 0,52)
Laser vs. Placebo Treatment -2,81 (-4,41 ; -1,24)
Combination Therapy -3,47   
      Figure 4: Pair-wise Meta-Analysis of Clinical Effectiveness for Different In-office 
Treatments of DHS (Lin et al. 2013) 
  
3.3.3 Meta-Study Pain Scale: Standardized Mean Difference (SMD) 
The pain scale for measuring the clinical effectiveness of DHS treatment that was used in 
Lin’s meta-analysis needs some further explanation to ensure sure that results are cor-
rectly interpreted. Basically, a meta-analysis is a statistical evaluation aiming at the ag-
gregation of results of different independent single studies (e.g. clinical trials) for further 
analysis and interpretation. In many cases however, different clinical studies may use 
different clinical measurement (i.e. scales in the field of pain) as well as clinical end 
points. Aggregating clinical data and results therefore presents a challenge, and a common 
“denominator” needs to be defined that allows aggregating the data.  
In Lin’s meta-analysis, two different pain scales were used in the underlying clinical tri-
als: 
 Verbal Rating Scale (VRS): Uses verbal descriptions (None, Mild, Moder-
ate, Severe Pain) according to (Holland et al. 1997). 
 Visual Analogue Scale (VAS): Uses a line of 10 cm; patients mark the pain 
presentation on the line (Scott and Huskisson 1976) 
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The Standardized Mean Difference (SMD) pain scale was introduced by Lin as a way 
to aggregate the data at the meta-level. The standardized mean difference “can be viewed 
as the mean difference that would have been obtained if all data were transformed into a 
scale where the standard deviation within-group was 1.0” (Lin et al. 2013).  
 
 
Figure 5: SMD, VRS and VAS Pain Scales – taken from (Lin et al. 2013) p.5) 
As a result, calculated effects and standardized mean differences that are used in the 
model have to be considered as “numbers”, which are not necessarily related anymore to 
the original measurement scale. As can be seen in Figure 5, a pain reduction of e.g. 3.0 
on the SMD Pain Scale could have enough impact on the VRS Pain to reduce “medium 
moderate” pain to “medium mild” pain.   
3.4 Cost Modeling in the Context of the German Health Care 
System 
 
This dissertation accounts for DHS treatment as listed in the German fee schedule for 
dentists GOZ and BEMA (KZBV 2018). “GOZ is uniformly valid throughout Germany 
and constitutes the medical fee schedule for privately insured patients” (Listl and 
Faggion 2010). It rules that basically all dental treatments are to be accounted for accord-
ing to GOZ, unless there is another federal law that constitutes “something different”, 
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which is the case for BEMA. BEMA is an agreement between the Federal Union of Public 
Dentists and the Union of Public Health Insurances and defines medical fees for publicly 
insured patients. GOZ and BEMA use an activity-based costing system, which means 
that activities that can be charged to patients are defined in GOZ and BEMA and total 
costs arising from a treatment are defined by adding up the activities that were performed.  
In general, treatment for privately insured patients is more costly, since e.g. treatment is 
performed by chief dentists and more time can be allocated to the patient by the dentist, 
which allows for an increased time factor that results in higher costs. Furthermore, it 
should be stated that every publicly insured patient can request privately insured treatment 
standards according to GOZ, However, the difference between GOZ and BEMA needs to 
be covered by the patient privately. 
The cost arising from DHS treatment depends on the insurance type of the patient (pub-
licly or privately insured) and on whether special treatment agents (e.g. laser) are re-
quested by the patient or not. To take these differences into account, two different sce-
narios are created in order to show a simplified monetary reflection of reality for DHS 
treatment: 
 
Scenario A: In the publicly insured patient scenario, basic treatment and basic 
treatment agents are accounted for according to BEMA. Laser treat-
ment is not covered by public health insurance and must be paid for 
privately according to GOZ. 
 Scenario B: In the privately insured patient scenario, basic treatment, basic treat-
ment agents and laser treatment are accounted for according to GOZ. 
 
Cost of activities during DHS treatment is calculated according to GOZ and BEMA on 
the basis of the following formula (Bundesgesetzblatt 2001): 
Cost (GOZ, BEMA) =  p (GOZ, BEMA) * µ * π 
 p (GOZ / BEMA) is the chargeable item points for a certain activity according to 
GOZ/BEMA 
 µ is the monetary conversion factor (€ 0.0562421 per GOZ item point and € 0.95 
according to BEMA) 
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 π is the treatment time factor, dependent on the complexity of the individual case” 
(π=1 with GOZ, π = 2.3 or 3.5 with BEMA) 
 
The standard treatment process is modeled by adding up activities i.e. cost drivers: 
 Anamnesis and consulting (BEMA: Ä1, GOZ: 0010) 
 Dentist performs symptom-specific intra-oral inspection (BEMA: Ä5, GOZ: 
0010) 
 Vitality testing for differential diagnosis (GOZ: 0070, BEMA: ViPr) 
 Treatment of hypersensitive teeth (BEMA: ÜZ, GOZ: 2010) 
3.5 Assumptions for Modeling of DHS Treatment 
 
The following further assumptions for cost modeling are made: 
 Hypersensitive teeth are present in both the maxilla and mandible (upper and 
lower jaw). 
 4+ teeth are hypersensitive, which allows an increased treatment time factor of  π 
= 3.5.  
 One treatment - one effect assumes that there is no follow-up treatment needed 
in the model and the clinical effect is reached by one in-office-treatment session. 
 Cost modeling of laser treatment: according to current GOZ and GEMA regu-
lations, the inclusion of laser for DHS treatment must not be accounted for as a 
separate item and cannot be charged to the patient. However, laser treatment for 
DHS is a fairly new field and GOZ and GEMA regulations do not yet fully take 
write-off of laser equipment into account at the time when this model was created. 
Therefore, accounting of laser treatment in the field of DHS is considered to be 
understated in GOZ and BEMA. This is further backed by the fact that the Ger-
man Society for Dental Treatment with Laser in 2014 petitioned for an update of 
GOZ accounting standards and for the inclusion of laser treatment in areas where 
clinical effectiveness of later treatment has already been proved. As a result of 
this petition, 9 treatment items were included in GOZ which allow to account for 
laser equipment (Esser 2014). Economic analysis requires a cost model that allows 
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encoding reality in a formal model. Therefore, this thesis will use the average cost 
of 9 treatment items for which laser usage has been included in 2014. The cost 
that will be used in this model is € 16.19 for laser treatment. 
3.6 Cost Modeling of DHS Treatment 
 
Taking all previous assumptions into account, a DHS treatment session would be ac-
counted for as follows: 
 
   
Figure 6: DHS Treatment Cost According to GOZ and BEMA 
  
          
  DHS treatment without laser: Privately insured – GOZ π = 2.3 π = 3.5   
  anamnesis & consulting € 10.72 € 10.72   
  intra-oral inspection € 10.72 € 10.72   
  vitality testing € 6.47 € 6.47   
  DHS treatment (1x per jaw) € 6.47 € 19.68   
          
    € 34.38 € 47.59   
          
  DHS treatment with laser: Privately insured – GOZ π = 2.3 π = 3.5   
  anamnesis & consulting € 10.72 € 10.72   
  intra-oral inspection 10,72 € 10,72 €   
  vitality testing 6,47 € 6,47 €   
  DHS treatment (1x per jaw) 6,47 € 19,68 €   
  Laser treatment 16,19 € 16,19 €   
    50,57 € 63,78 €   
          
  DHS treatment without laser: Publicly insured – BEMA     
  anamnesis & consulting  8,55 €   
  intra-oral inspection  5,70 €   
  vitality testing  1,92 €   
  DHS treatment  5,70 €   
          
     19,95 €   
          
  DHS treatment with laser: Publicly insured – BEMA     
  anamnesis & consulting  8,55 €   
  intra-oral inspection  5,70 €   
  vitality testing  1,92 €   
  DHS treatment  5,70 €   
  Laser treatment  16,19 €   
     36,14 €   
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3.7 Deciding on Cost Effectiveness 
 
In this section, the cost effectiveness of Scenarios A and B is discussed and the ratio of 
cost to effectiveness of different treatment alternatives is calculated according to the fol-
lowing formula: 
 
Cost Effectiveness Ratio =  
Cost
Clinical Effectiveness
 
 
 
In the model, cost is measured in “EUR” and effectiveness by the “SMD Pain Scale Re-
duction”. The decision tree that is used is very simple and includes only one decision, 
which is which treatment alternative to take. 
 
 
Figure 7: DHS Decision Tree 
To incorporate uncertainties regarding the effect of SMD pain reduction, a triangular dis-
tribution function was included for each health outcome. The upper and lower bounds 
equate to the 95% confidence intervals and the most likely point within each distribution 
is defined by the point estimate for the reduction of standardized mean derived from the 
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VAS and VRS scale as reported in section 2.3.3. Furthermore, a Monte Carlo simulation 
with 10,000 repetitions is conducted. 
3.8 Scenario A: Cost Effectiveness Plane for a Publicly 
Insured Patient and ICER Analysis 
 
The cost effectiveness plane shows the cost effectiveness frontier for Scenario A (publicly 
insured patient). In general, it can be said that the more to the right and the more to the 
bottom an alternative is, the better is the respective cost effectiveness.  
 
 
Figure 8: Cost Effectiveness Plane DHS Treatment (Scenario A) 
It can be concluded that treatment options III & IV (chemical occlusion and nerve de-
sensitization) are dominated by treatment options II & V (physical occlusion and laser 
treatment). In other words, nerve desensitizing, chemical occlusion and physical occlu-
sion all cost the same, but physical occlusion “works the best”. Furthermore, a second 
treatment alternative that dominates chemical occlusion and nerve desensitization is laser 
treatment. However, laser treatment is not only better than physical occlusion but also 
significantly more expensive. As a first indicator, the slope between physical occlusion 
and laser treatment can be used: the steeper the slope between two treatment alternatives, 
the more expensive it is to get from one treatment option to the other.  
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If a decision maker has to decide between two different cost-effective alternatives, in this 
case physical occlusion and laser treatment, the concept of Incremental Cost Effective-
ness Ratio (ICER) can be consulted to gain further insights. The ICER is defined as the 
ratio of incremental cost arising from moving from one treatment alternative to the next, 
set in relation to the effectiveness gain arising from moving from one treatment alter-
native to the next alternative (see section 2.1.1): 
 
 
ICER =
Cost(Alternative2) − Cost(Alternative1)
Effect(Alternative2) − Effect(Alternative1)
 
 
 
The ICER of physical occlusion vs. placebo in this model is calculated at 7.76 EUR/1.0 
SMD Pain Scale unit reduction. 
The ICER of laser treatment vs. physical occlusion in this model is calculated as 6.4 
EUR/0.1 SMD Pain Scale unit reduction, which is represented by the steep slope be-
tween the two alternatives in the graph. Transposing this result to a percentage view for 
a better understanding, the following conclusion can be drawn: If patients wants to fur-
ther reduce the pain by 10 percentage points (%), the cost increases by 87 percentage 
points (%). 
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3.9 Scenario A: Sensitivity Analysis (Hypothetical WTP)  
 
The concept hypothetical Willingness to Pay (WTP) will be introduced for further 
analysis and for inclusion of budgetary constraints into the model.. WTP is the max-
imum price at which a consumer is willing to “buy” a product/service (Varian 2003). 
Whenever a good/service is exchanged between a buyer and a seller, the buyer’s 
willingness to pay meets the seller’s willingness to sell. WTP can be used in CEA to 
analyze decisions under budget restrictions (Gafni 1998). 
The following figure depicts the cost acceptability curve along WTP. Put in other 
words, the graph shows us which treatment alternative should be preferred under a given 
Willingness to Pay. Furthermore, the graph assigns a probability to a treatment option 
being cost-effective given a certain WTP. 
 
 
Figure 9: Cost Effectiveness Acceptability Frontier for Scenario A 
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 Laser treatment is the most cost-effective therapeutic choice if the patient is 
willing to pay more than 63 EUR for the incremental SMD Pain reduction (re-
duction increment on the SMD Pain Scale = 1.0) 
 Physical occlusion is the most cost-effective therapeutic choice given that the 
patient is willing to pay less than 63 EUR for the incremental SMD pain reduc-
tion (reduction increment on the SMD Pain Scale = 1.0) 
 
However, it has to be noted that this analysis is based on the fact that pain reduction can 
be continuously reduced by multiplying or adding treatment sessions. In reality, pain re-
duction is limited, with the ultimate pain reduction attainable lying at a reduction of 
2.81, which can be achieved through laser treatment. 
The maximum increment that can be reached is 0.24. Transposing the results from the 
graph above to the DHS treatment scenario, it makes sense to shift from pain reduction 
increments of 1.0 to 0.1. 
The transposed statements would be as follows: 
 Laser treatment is the most cost-effective therapeutic choice if the patient is 
willing to pay more than 6.4 EUR for the incremental SMD pain reduction (re-
duction increment on the SMD Pain Scale =0.1) 
 Physical occlusion is the most cost-effective therapeutic choice if the patient 
is willing to pay less 6.4 EUR for the incremental SMD pain reduction (reduc-
tion increment on the SMD Pain Scale = 0.1). 
3.10 Scenarios B: Cost Effectiveness Plane for a Privately 
Insured Patient 
 
The cost effectiveness plane shows the cost effectiveness frontier for a Scenario A (pri-
vately insured patient). In general, it can be said that the more to the right and the more 
to the bottom an alternative is, the better is the respective cost effectiveness.  
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Figure 10: Cost Effectiveness Plane DHS Treatment (Scenario B) 
The results of the cost effectiveness analysis for a privately insured patient are the 
same as for a publicly insured patient, but at a higher cost level. It can be concluded 
that Treatment Options III & IV (chemical occlusion and nerve desensitization) are 
dominated by treatment options II & V (physical occlusion and laser treatment). Put 
in other words, nerve desensitizing, chemical occlusion and physical occlusion all cost 
the same, but physical occlusion “works the best”. Furthermore, a second treatment 
alternative that dominates chemical occlusion and nerve desensitization is laser treat-
ment. However, laser treatment is not only better than physical occlusion but also signif-
icantly more expensive. 
Since ICER is not significantly different for a publicly insured patient, please refer to the 
ICER analysis in section 2.8. 
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3.11 Scenario B: Sensitivity Analysis (Hypothetical WTP) 
 
Analogously to Scenario A, Willingness to Pay is analyzed and the cost acceptability 
frontier along WTP is depicted: 
 
 
Figure 11: Cost Effectiveness Acceptability Frontier (Scenario B) 
In general, it can be said that shifting from a publicly insured to a privately insured 
cost scenario does not make a difference regarding the cost effectiveness of treat-
ment choices. Equivalent to Scenario A, laser treatment and physical occlusion are the 
dominant treatment alternatives. The only difference between Scenario A and Scenario 
B is that the absolute cost level is higher. 
The following conclusions can be drawn for the privately insured patient scenario: 
 Laser treatment is the most cost-effective therapeutic choice given that the 
patient is willing to pay more than 7.4 EUR for the incremental SMD pain re-
duction (reduction increment on the SMD Pain Scale =0.1) 
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 Physical occlusion is the most cost-effective therapeutic choice given that the 
patient is willing to pay less than 7.4 EUR for the incremental SMD pain re-
duction (reduction increment on the SMD pain Scale = 0.1).  
To sum up the results for a privately insured patient, besides minor differences in 
the Willingness to Pay analysis the results of the overall cost effectiveness do not 
change in a privately insured patient scenario when treating DHS.  
3.12 Overall Summary 
 
The model clearly shows that within this model, nerve desensitization and chemical 
occlusion are dominated and ineffective compared with physical occlusion and laser 
treatment as alternatives for DHS treatment. Physical occlusion and laser treatment are 
cost-effective choices. The technical analysis can be summed up as follows: 
 Under a restricted budget, a choice between physical occlusion and laser 
treatment is recommended. 
 ICER analysis publicly insured patient: The ICER for physical occlusion 
compared with placebo is 7.76 EUR / 1.0 SMD pain reduction 
 ICER analysis publicly insured patient: if a patient wants to further reduce 
the pain by 9.3 percentage points (%) by choosing laser treatment over phys-
ical occlusion, the cost increases by 81.1 percentage points (%).  
 Publicly insured patient decision under budget restrictions: for a Willingness 
to Pay < 6.3 EUR for the improvement of an additional 0.1 of SMD pain reduc-
tion, the patient should choose physical occlusion. 
 Publicly insured patient under budget restrictions: for a Willingness to Pay > 
6.3 EUR for the improvement of an additional 0.1 of SMD pain reduction, the 
patient should choose laser treatment.  
 Privately insured patient under budget restrictions: for a Willingness to Pay 
< 7.4 EUR for the improvement of an additional 0.1 of SMD pain reduction, the 
patient should choose physical occlusion. 
 Privately insured patient under budget restrictions: for a Willingness to Pay 
> 7.4 EUR for the improvement of an additional 0.1 of SMD pain reduction, the 
patient should choose laser treatment.  
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 Under an unrestricted budget, the patient should choose laser treatment. 
 It was shown that the effectiveness scenarios for privately and publicly in-
sured patients are the same; however the cost level for a privately insured 
patient is higher. 
 
Key Findings: Based on the model, cost effectiveness analysis shows that in a scenario 
where DHS is treated, physical occlusion and laser treatment should be preferred 
treatment alternatives. From an ICER perspective, a clinical decision maker treating for 
DHS should always opt for physical occlusion. The most commonly used agent for phys-
ical occlusion is a dentin-bonding agent. However, clinical practice shows that chemi-
cal occlusion is the standard treatment options. Physical occlusion should be the 
standard treatment of choice when treating DHS. However, in extreme cases of hy-
persensitivity, laser treatment is always an additional option (second best), but the steep 
ICER should be considered by a decision maker. 
3.13 Model Evaluation 
 
Based on latest available clinical evidence and a cost model based on GOZ and BEMA, 
a cost effectiveness analysis of DHS treatment alternatives was performed. The question 
is whether all factors, that are key characteristics of good cost effectiveness analysis were 
fulfilled (Tonmukayakul et al. 2015):  
Factor 1 transparency of cost calculations: cost calculation was provided for in de-
tail (see section 2.6). 
Factor 2 cost discounting: discounting was not required. No information was given 
about whether the effects last one or more years. In general, clinical practice shows 
that the effects of hypersensitivity treatment are rather short-term effects, lasting less 
than one year. The model was based on the assumption “one treatment - one effect”, 
therefore, no discounting is applicable and needed. 
Factor 3 quality of underlying clinical endpoints: Lin’s meta-analysis was checked 
thoroughly by investigating clinical endpoints in underlying studies. Additionally, the 
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introduction of a meta-level pain scale properly aggregated clinical endpoints on the 
meta-level. 
However, CEA models can only be as good as their underlying data. It is possible that 
the lack of evidence in certain areas might have limited this cost effectiveness analysis. 
To further reduce uncertainty in the model and to improve cost effectiveness analysis, 
enhanced clinical trials are needed and their data needs to be implemented into the mod-
els. However, as of today, and until further clinical studies are available, physical occlu-
sion has the highest probability of being cost-effective and should therefore be chosen. 
Certain limitations to this model need to be discussed:   
First, a limitation of this analysis is that categories were used for effectiveness, e.g. 
physical occlusion category. Each category summed up different treatment agents 
into a category, and confidence intervals for a category were quite large. If analysis 
could be performed on the treatment agent level, variances could be reduced and fur-
ther insight could be gained.  
Second, using GOZ and BEMA for cost calculations “ignores” the fact that different 
treatment alternatives can have different “price tags”. If cost information was availa-
ble on the treatment agent level, e.g. through micro-costing analysis, this could have 
an impact to the result of this model. But as micro-costing is not available at the treat-
ment level, the best available information as of today was used for this model.  
Third, it can be argued that cost effectiveness was not measured accurately in appro-
priate physical units, but on a more abstract meta-level (standardized meta-level pain 
scale). Since this model was based on a meta-analysis, a common denominator was 
needed for heterogeneous underlying pain scales. But even though an “abstract” scale 
was used, the impact on health outcomes could still be analyzed.  
Fourth, the model assumed “one treatment - one effect”, which means that there is 
no follow-up treatment included in the model (e.g. 2nd application of an agent after 6 
months). As a result, the decision tree and the model were designed for analyzing 
a “one-off” decision. No data on how long the treatment effect persists over time was 
included in the model. To further enhance the model, clinical data is required on 
how long the clinical effects of DHS treatment last. There are currently no reliable 
longitudinal studies on the long-term effects of DHS treatment available. Longitudi-
nal studies of the clinical effectiveness and reliable recommendations on follow-up 
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treatments could have a significant impact on the cost and effectiveness of the model. 
With this information, an extended cost effectiveness analysis could be implemented 
and extended research could further support the finding of this study that physical 
occlusion and laser treatment are not only cost-effective choices in a one-off scenario, 
but also in the long run.  
The conclusion can be drawn that at the current state and without knowledge about how 
long the effects last, the results of this study can only support short-term decision 
making. In order to provide proper guidelines to clinical decision makers, a model is 
needed that includes the information on how long the effects of the treatments last 
(long term). An extended long-term model that supports the findings of this short-term 
model could improve decision making for dentin hypersensitivity treatments, with 9 mil-
lion treatments being performed every year in Germany alone. A long-term model could 
support a paradigm shifts towards using physical occlusion as the standard treat-
ment option for dentin hypersensitivity, which could help gain 10% more effective-
ness, everything else being equal, by shifting the treatment decision from chemical to 
physical occlusion. 
How the results of this dissertation can be implemented in clinical practice will be dis-
cussed in the concluding section (chapter 6) of this dissertation. 
From a modelling perspective, this chapter found that the long-term impact was not as-
sessed with the model due to data limitations. How a model can be developed when ap-
propriate long-term clinical data is available will be shown in the next chapter. 
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4 Deciding on Cost Effectiveness of Therapeutic 
Alternatives in Direct Pulp Capping (Open Pulp 
Treatment): Mineral Trioxide Aggregate vs. Calcium 
Hydroxide (Transition State Modeling) 
 
4.1 Background 
 
In the clinical situation of an open pulp, pulp capping and root canal treatment are 
different treatment alternatives that can be selected by clinical decision makers. Ac-
cording to the latest available data from the German Federal Union of Public Dentists 
(KZVB), about 7 million root canal treatments are performed and accounted for every 
year (KZBV 2018). In contrast, pulp capping treatments were performed and accounted 
for 775,600 times within the public German healthcare context in 2013 (KZBV 2014).  
Pulp capping itself is significantly less expensive than root canal treatment, but risk 
of failure can vary, depending on the material used for pulp capping. A recent long-
term study has shown that the material used in direct pulp capping treatment has a sig-
nificant effect on the clinical performance of the treatment of an open pulp (Mente et 
al. 2014). 
In addition to differences in clinical effectiveness, different capping materials also have 
different price tags. Modern materials that can be used for direct pulp capping have a 
higher price tag. The question is whether this additional spending is allocated towards the 
right material? 
Also, the overall costs and benefits of an overall treatment strategy are highly dependent 
on the sequence of the first chosen treatment option in the clinical situation of treatment 
an open pulp. It is not trivial to take all these interdependencies into account without a 
proper decision rationale.  
Therefore, an economic evaluation model will be established to support decision mak-
ing for direct pulp capping. It will help to clarify if and under which budget restriction it 
makes sense for a decision maker to invest in a more expensive material. The focus of 
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this analysis lies on the implementation of long-term data and the highest evidence level 
that is available for clinical effectiveness for direct pulp capping as of today. 
4.2 Open Pulp and Direct Pulp Capping as a Treatment Option 
from a Medical Perspective 
 
This section describes what direct pulp capping is from a medical perspective and in 
which clinical situation is it needed. The clinical situation where pulp capping is needed 
is described by the term open pulp, or pulpa aperta (latin). This describes the state when 
the pulp of a tooth is exposed (opened) due to e.g. deep caries treatment (caries pro-
funda), dental trauma, or other causes. If no treatment is performed, harmful germs 
(bacteria, viruses) from the oral flora will be able to enter the pulp. As a consequence, 
the pulpal tissue will be attacked by these germs, which will ultimately lead to an infection 
and in most cases also to destruction of the pulpal tissue (Hargreaves and Louis H. 
Berman 2015). 
Direct pulp capping is one therapeutic treatment option, and a frequently performed 
treatment alternative to more invasive root canal treatment (Mente et al. 2014). It 
should be clearly stated that pulp capping treatment is not only an alternative to the above 
mentioned treatments, but is also an attempt to preserve and maintain the vitality of 
the tooth with an open pulp (Hargreaves and Louis H. Berman 2015). Root canal treat-
ment or further clinical procedures might be ultimately necessary if pulp capping fails 
and are important next-step treatment options – under certain conditions.  
There are several clinical prerequisites that must be fulfilled for the indication of direct 
pulp capping, the most important of which include (EuropeanSocietyOfEndodontology 
2006): 
 
 No caries remaining in the cavity 
 Vitality & ability of the pulp to regenerate 
 No pre-existing endodontic pre-condition (e.g. pulpitis) 
 Possibility to keep treatment sterile (e.g. by placing rubber dam) 
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How pulp capping works will be briefly explained. As per the clinical definition, the pulp 
capping treatment itself is described as “a procedure in which the pulp is covered with 
a protective dressing placed directly over the pulp at the site of exposure” 
(EuropeanSocietyOfEndodontology 2006). A second layer is then placed on top of the 
protective dressing, covering the surrounding dentin and the first layer. The second layer 
serves as a “bandage” and is ideally made of an adhesive permanent restoration (e.g. 
dental composite material). It needs to be placed on the same day if the highest available 
clinical survival rate is aspired to (Welbury 2003). 
Bringing all pre-requisites together, pulp capping treatment involves applying a seal 
to an open pulp and leaving the pulp in a condition with limited to no bacterial infec-
tion, so that it can heal. This principle is supported by the very early findings of Kake-
hashi et al. in 1965 (Kakehashi et al. 1965), which showed that opened pulps of germ-
free rats (gnotobiotic rats) can heal under sterile conditions due to the regenerative power 
of dentine, but that in contrast if the exposed pulp is exposed to micro-organisms, necrosis 
is an inevitable result (Trohorsch et al. 2012). 
4.2.1 Alternative Treatment Options – Indirect Pulp Capping 
For reasons of completeness, it should be mentioned that in the dental medical literature 
the clinical procedure of indirect pulp capping is often mentioned as a treatment option 
for pulpa aperta situations. However, this treatment is not considered a valid treatment 
option, as a study (Mente 2014) showed bad prognosis for teeth that were indirectly pulp 
capped. Indirectly pulp capped teeth have an approximately 3.2 times higher risk of fail-
ure than directly pulp capped teeth. This clinical procedure is obsolete today and should 
not be performed anymore. Therefore, indirect pulp capping will be excluded from the 
model. 
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4.3 Health Outcomes and Clinical Effectiveness of Open Pulp 
Treatment 
4.3.1 Material Selection for Clinical Outcomes of Direct Pulp Capping – 
Introduction 
The most widely accepted material currently used by dentist for direct pulp capping as a 
protective dressing material is calcium hydroxide (CaOH). Mineral trioxide aggregate 
(MTA) is also being increasingly used as a popular alternative to CaOH. There are several 
other pulp capping materials being used as of today, but this thesis will focus only on the 
most commonly used materials in an everyday dental clinic environment.  
The treatment outcomes of CaOH vs. MTA has long been a matter of dispute amongst 
dental practitioners and scientists. The first long-term studies and clinical data on treat-
ment outcome have been published by J. Mente, providing an important insight into this 
matter of dispute (Mente et al. 2014). Mente analyzed clinical data from 2001 to 2011. 
The study, as of today, represents the largest controlled clinical trial comparing CaOH vs. 
MTA in pulp capping with follow-up periods from 2 years up to 10 years.  
4.3.2 MTA and Calcium Hydroxide: Clinical Outcome and Reasons for 
Different Clinical Performance 
Mente’s long-term research shows the following clinical outcome, indicating that MTA 
materials achieve better long-term results for direct pulp capping than CaOH: 
 
 
  
Clinical Success Rate  
(10 years) 
95% Confidence Interval 
 [CI] 
Mineral Trioxide Aggregate 80.5% 74.5–86.5 
Calcium Hydroxide 59% 46.5–71.5 
 
Figure 12: Clinical Success Rate MTA vs CaOH in Direct Pulp Capping 
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An examination of this study and several other studies dealing with the material proper-
ties of MTA and CaOH allows us to infer that CaOH must have several disadvantages 
that lead to a weaker clinical performance (Bakland and Andreasen 2012). The most im-
portant ones should be mentioned at this point for a deeper understanding of how CaOH 
and MTA work as a material: 
 Ability to form dentin bridge: CaOH’s pH of 12.5 leads to a liquefaction and 
coagulation necrosis zone in the area where CaOH meets the pulp. This initiates 
wound healing through growth factors resulting in a calcification reaction and 
the formation of a hard tissue bridge. The hard tissue bridge is the biological seal 
of the pulp. The dentin bridge is formed faster when MTA is used.  
 Antibacterial effect (due to pH) leaves a bacterial-free environment of the pul-
pal amputation site. MTA tends to last longer than CaOH, and therefore the anti-
bacterial effect of MTA also lasts longer. 
 Micro-leakage and tunnel defects: CaOH materials tend to dissolve over time.  
Micro-leakage and tunnel defects are pathways for bacteria into the pulp, which 
can ultimately result in pulpitis. Furthermore, the antibacterial effect is weak-
ened once CaOH dissolves. MTA in contrast forms a tighter seal with dentin and 
the MTA seal minimizes the risk of bacterial penetration to the pulp through mi-
cro-leakage and tunnel defects.   
 Dentin softening effect of CaOH (Yoldas et al. 2004) means a higher risk of 
fracture. In contrast, no softening effect of MTA is known. 
4.3.3 Alternative or Consecutive Treatment Options in Case of Failure of 
Pulp Capping  
As mentioned above, pulp capping treatment can fail. Remaining treatment options and 
follow-up treatments are as follows (Salehrabi and Rotstein 2004):  
1. Root canal treatment – description and clinical effectiveness 
Root canal treatment is a therapy option for an inflamed pulp and describes the pro-
cess of carefully removing the pulp inside the tooth. Tooth canals are cleaned, disin-
fected and shaped, and a filling is placed to finally seal the root canal space to avoid 
further invasion of bacteria (AmericanAsscociationOfEndodontists 2018)  
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The latest meta-analysis of the clinical effectiveness shows an 85.8% estimated suc-
cess rate (Ng et al. 2007) with 95% CI [81,8 ; 89,9] based on clinical and “loose” 
radiographic outcome measures. This aggregated number is most representative for a 
4-year follow-up period after treatment.  
2. Root canal revision – description and clinical effectiveness 
If root canal treatment fails, further treatment options are root canal revision and 
endodontic re-treatment. The pooled estimated survival rate of endodontic revision 
is 77.2% (Ng et al. 2008) [95% CI: 61.1%, 88.1%] based on loose criteria. In this 
meta-analysis, follow-up was between 6 months and 20 years. Due to the underlying 
data, attempts to pool data by follow-up period were not possible. However, 8 out of 
17 included clinical trials with a follow-up period of at least 4 years and therefore it 
will be assumed for further economic modeling that the given 77.2% survival rate 
is represented at a 4 year follow-up after treatment. 
3. Extraction – description and clinical effectiveness 
Extraction of a tooth is always the last resort in dental medicine for the survival of a 
single tooth. The extraction of a tooth has an assumed clinical effectiveness of 0.0% 
in this model. 
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4.3.4 Clinical Decision Tree: Direct Pulp Capping and Post-Direct Pulp 
Capping Treatments 
 
A clinical decision tree is drawn that will be used in this model. It starts with the clinical 
condition of an open pulp and follows the different treatment options resulting in different 
health states. 
 
 
Figure 13: Clinical Decision Making for Treatment in Case of Pulpa Aptera (Open 
Pulp) 
 
The model ends with the extraction of a tooth or the patient’s death (everything else be-
ing equal).  
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4.4 Cost Modeling Direct Pulp Capping 
 
The model accounts for direct pulp capping and post-direct pulp capping treatment as 
listed in the GOZ and BEMA Costs will be modeled analogously to the previous chapter; 
for further cost modeling details please refer to section 2.4. 
For this cost effectiveness analysis, a GOZ-only scenario will be developed due to 
the fact that most activities used in the model are not accounted for in BEMA. It was 
shown in Chapter 2 that shifting from a publicly insured patient scenario to a privately 
insured patient scenario only impacts a cost shift of all costs but does not change overall 
cost effectiveness. Therefore, cost of activities is calculated according to GOZ on the 
basis of the following formula (Bundesgesetzblatt 2001): 
Cost (GOZ) = p (GOZ) * µ * π 
 p (GOZ) is the chargeable item points for a certain activity according to the GOZ  
 µ is the monetary conversion factor (€ 0.51 per GOZ item point) 
 π is the treatment time factor, dependent on the complexity of the individual case 
(π=2.3 or 3.5).  
4.4.1 Assumptions for Modeling 
The following assumptions were used for the modeling: 
 All treatment happens within the context of the German healthcare system 
 Male patient, 30 years old 
 Remaining life expectancy of patient is 48.55 years (StatistischesBundesamt 
2015) 
 Open pulp of a lower jaw molar with 3 root canals 
 Direct pulp capping treatment is conducted in compliance with latest findings to 
achieve highest clinical outcome of treatment – i.e. capping treatment in first ses-
sion 
 Root canal treatment is conducted in 2 sessions and 3 root canals are treated 
 Cost Estimate for MTA: 2 factors driving MTA cost in this model, 1) increased 
material cost directly charged to the patient and 2) excess time needed for MTA 
handling. Increased material cost was estimated to be 36.50 EUR, which corre-
sponds to the average sales price of 0.5 g MTA (Pro Root MTA – own Micro 
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Costing Analysis). To account for the additional time for MTA placement, the 
treatment time factor was shifted from 2.3 to 3.5 according to the fee scale for 
dentists (GOZ). Both factors result in an additional cost of 50 EUR for MTA 
charged to the patient in the model. 
 
4.4.2 Standard Treatment Process for Modeling 
A standard treatment process is modeled by adding up activities, i.e. cost drivers 
for the different treatments:  
1. Treatment 1: Direct Pulp Capping 
 Anamnesis and consulting (GOZ 0010, 100 points) 
 Symptom-specific intra-oral inspection (GOZ 0010, 100 points) 
 Vitality testing for differential diagnosis (GOZ 0070, 50 points) 
 Local anesthesia lower jaw (GOZ 0100, 70 points) 
 Placement of rubber dam (GOZ 2040, 65 points) 
 Treatment of an open vital pulp (GOZ 2340, 200 points) 
 MTA capping expense (50 EUR) 
 Adhesive restoration (GOZ 2100, 642 points) 
 
2. Treatment 2: Root Canal Treatment (ZMK 2011) 
 Anamnesis and consulting (GOZ 0010, 100 points) 
 Symptom-specific intra-oral inspection (GOZ 0010, 100 points) 
 Vitality testing for differential diagnosis (GOZ 0070, 50 points) 
 Local anesthesia lower jaw (GOZ 0100, 70 points) 
 Placement of rubber dam (GOZ 2040, 65 points) 
 Trepanation (GOZ 2390, 65 points) 
 VitE 3x (GOZ 2360, 110 points per canal) 
 Root canal treatment incl. rinsing 3x (GOZ 2410, 392 points per canal) 
 Electromagnetic length determination 3x (GOZ 2400, 70 points per canal) 
 Ultrasonic activated rinsing 3x (GOZ 2420, 70 points per canal) 
 Med treatment (CaOH & CHX) (GOZ 2430, 204 points) 
 Temporary filling (GOZ 2020, 98 points) 
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 X-ray for diagnosis, length check & Master Point Check, 3x (GOZ 5000, 50 
points per X-ray) 
 Application of a microscope (GOZ 0110, 400 points) 
 Root canal filling 3x (Guttapercha) (GOZ 2440, 258 points per filling) 
 Adhesive restoration (GOZ 2100, 642 points) 
 
3. Treatment 3: Root Canal Revision 
 Anamnesis and consulting (GOZ 0010, 100 points) 
 Symptom-specific intra-oral inspection (GOZ 0010, 100 points) 
 Vitality testing for differential diagnosis (GOZ 0070, 50 points) 
 Placement of rubber dam (GOZ 2040, 65 points) 
 Trepanation (GOZ 2390, 65 points) 
 Root canal treatment incl. rinsing 3x (GOZ 2410, 392 points per canal) 
 Electromagnetic length determination 3x (GOZ 2400, 70 points per canal) 
 Ultrasonic activated rinsing 3x (GOZ 2420, 70 points per canal) 
 Med treatment (CaOH & CHX) (GOZ 2430, 204 points) 
 Temporary filling (GOZ 2020, 98 points) 
 X-ray for diagnosis, length check & master point check, 3x (GOZ 5000, 50 points 
per X-ray) 
 Application of a microscope (GOZ 0110, 400 points) 
 Root canal filling 3x (Guttapercha) (GOZ 2440, 258 points per filling) 
 Adhesive restoration (GOZ 2100, 642 points) 
 
4. Treatment 5: Extraction 
 Anamnesis and consulting (GOZ 0010, 100 points) 
 Dentist performs symptom-specific intra-oral inspection (GOZ 0010, 100 points) 
 Vitality testing for differential diagnosis (GOZ 0070, 50 points) 
 X-ray (GOZ 5000, 50 points) 
 Local anesthesia lower jaw (GOZ 0100, 70 points) 
 Extraction & wound suture (GOZ 3010, 110 points) 
Taking all previous assumptions into account, an open pulp capping treatment session 
would be accounted for as follows: 
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Figure 14: Pulp-Capping and Post-Pulp Capping Treatment Cost According to 
GOZ 
  Direct Pulp Capping - CaOH Privately insured – GOZ GOZ Points Amount Multiplier Cost
Anamnesis & Consulting Ä1 100 2,3 12,94 €
Symptomspecific Diagnosis Ä5 100 2,3 12,94 €
Vitality Testing 70 50 2,3 6,47 €
Local Anästhesia Lower jaw 100 70 2,3 9,05 €
Rubber Dam 2040 65 2,3 8,41 €
Open Pulp Treatment 2340 200 2,3 25,87 €
Adhesive Restoration 2100 642 2,3 83,05 €
Total 158,72 €
  Direct Pulp Capping - MTA Privately insured – GOZ GOZ Points Amount Multiplier Cost
Anamnesis & Consulting Ä1 100 2,3 12,94 €
Symptomspecific Diagnosis Ä5 100 2,3 12,94 €
Vitality Testing 70 50 2,3 6,47 €
Local Anästhesia Lower jaw 100 70 2,3 9,05 €
Rubber Dam 2040 65 2,3 8,41 €
Open Pulp Treatment 2340 200 3,5 39,37 €
Adhesive Restoration 2100 642 2,3 83,05 €
MTA - Direct Cost for Material (0.5g) 36,50 €
Total 208,73 €
  Root Canal Treatment Privately insured – GOZ GOZ Points Amount Multiplier Cost
Anamnesis & Consulting Ä1 100 2,3 12,94 €
Symptomspecific Diagnosis Ä5 100 2,3 12,94 €
Vitality Testing 70 50 2,3 6,47 €
Local Anästhesia Lower jaw 100 70 2,3 9,05 €
Rubber Dam 2040 65 2,3 8,41 €
Trepanation 2390 65 2,3 8,41 €
VitEx ( per canal) 2360 110 3 2,3 42,69 €
Root Canal Treatment (3x) 2410 392 3 2,3 152,12 €
Electromagnetic Legth Determination  (per canal and session)2400 70 6 2,3 54,33 €
Ultrasonic Rinsing (per canal) 2420 70 3 2,3 27,16 €
Med 2430 204 2,3 26,39 €
Temporary Filling 2020 98 2,3 12,68 €
X-Ray (3x) 5000 50 3 2,3 19,40 €
Microscope 110 400 2,3 51,74 €
Root Canal Filling 2440 258 3 2,3 100,12 €
Adhesive Restoration 2100 642 2,3 83,05 €
Total 627,90 €
  Root Canal Re-Treatment Privately insured – GOZ GOZ Points Amount Multiplier Cost
Anamnesis & Consulting 10 100 2,3 12,94 €
Symptomspecific Diagnosis Ä5 100 2,3 12,94 €
Vitality Testing 70 50 2,3 6,47 €
Rubber Dam 2040 65 2,3 8,41 €
Trepanation 2390 65 2,3 8,41 €
Root Canal Treatment (3x) 2410 392 3 2,3 50,71 €
Electromagnetic Legth Determination 2400 70 3 2,3 9,05 €
Ultrasonic Rinsing 2420 70 3 2,3 9,05 €
Med 2430 204 2,3 26,39 €
Temporary Filling 2020 98 2,3 12,68 €
X-Ray (3x) 5000 50 2,3 6,47 €
Microscope 110 400 2,3 51,74 €
Root Canal Filling 2440 258 2,3 33,37 €
Adhesive Restoration 2100 642 2,3 83,05 €
Total 331,67 €
Extraction Privately insured – GOZ GOZ Points Amount Multiplier Cost
Anamnesis & Consulting 10 100 2,3 12,94 €
Symptomspecific Diagnosis Ä5 100 2,3 12,94 €
Vitality Testing 70 50 2,3 6,47 €
X-Ray 5000 50 2,3 6,47 €
Local Anästhesia Lower jaw 100 70 2,3 9,05 €
Extraction of Tooth with +1 Roots 3010 110 2,3 14,23 €
Total 62,09 €
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4.5 Markov Model (Transition State Model) 
 
A Markov transition state model (Sonnenberg and Beck 1993) was created using 
TreeAge Pro 2019. The model is based on the clinical decision tree in section 3.3.4. 
The model starts with the clinical situation of a tooth with an open pulp. In this situa-
tion, the clinical decision maker has the choice to 1) pulp cap the tooth with MTA; 2) 
pulp cap with CaOH; or 3) perform immediate root canal treatment. From these states, 
the tooth can then transition into the post-pulp capping or post-root canal treatment states 
(revision, extraction). Each transition of a health state is associated with a cost and 
effectiveness (it is assumed that when a transition happens, treatment is performed that 
has an associated cost and effectiveness). Transition probabilities to different states were 
defined using time-dependent survival functions, which were implemented into the 
model. For clinical effectiveness, triangular distributions were implemented into the 
model according to the 95% confidence interval. Cost was implemented according to 
GOZ calculations without any variance, but will later be analyzed under variance analy-
sis. One cycle in the state transition model equals one calendar year. 48.55 cycles were 
implemented according to the expected remaining tooth life in the model based on the 
life expectancy of a 30-year-old male patient. 
The Markov model was populated via a Monte Carlo simulation (sample + trial function 
of TreeAge 2019) and a population of 10,000 teeth was created. 
Future cost was discounted (2% p.a.), but effectiveness was not discounted (see sec-
tion 1.3.6). 
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The state transition model was implemented in Treeage Pro as follows and additional 
analyses were run on the model: 
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  Figure 15: Markov State Transition Model in TreeAge Pro 2019 
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4.6 Deciding on Cost Effectiveness 
 
4.6.1 Cost Effectiveness Plane 
The cost effectiveness plane shows the cost effectiveness frontier for the state transition 
model. In general, it can be said that the more to the right and the lower an alternative is, 
the better is the respective cost effectiveness. 
 
 
 
 
Figure 16: Cost Effectiveness Plane Direct Pulp Capping MTA vs. CaOH vs. Immediate 
Root Canal Treatment 
 
The depicted cost effectiveness plane can be analyzed as follows: 
 In a long-term model of an MTA pulp-capped molar tooth with remaining life 
expectancy of 48.55 years, 10.3 tooth life years on average can be gained for the 
average cost of 402 EUR. The effectiveness is gained by and cost is accrued for 
pulp capping and post-pulp capping treatment options. It should be noted that 
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these numbers are based on averages resulting from the Monte Carlo simulation 
of a sample population of 10.000.  
 MTA pulp capping dominates all other treatment options  
 
The cost effectiveness plane clearly shows that MTA pulp capping treatment domi-
nates both CaOH pulp capping and immediate root canal treatment. Therefore, MTA 
pulp capping has the highest likelihood to be the most cost-effective treatment alter-
native in this model.  
Results for dominated treatment options can be analyzed as follows: 
Immediate RCT: comes with a very high price tag. In the short run, immediate RCT 
might have a slightly higher clinical effectiveness than MTA treatment, but due to lower 
cost and higher effectiveness on first post-capping treatment, RCT is dominated by MTA 
treatment in the long run. 
CaOH: the result for CaOH in the state transition model can be explained as follows: Due 
to high failure rates (41%) in the first 10 years post-capping, many simulated teeth end 
up requiring root canal treatment. Even though substantial effectiveness is gained through 
root canal treatment, the cost for root canal treatment is high. Therefore, compared to 
MTA pulp capping, CaOH pulp capping ends up with a higher cost on average. With 
regard to effectiveness, the MTA pulp-capped tooth population has a serious head start in 
effectiveness that CaOH cannot catch up to, even if some teeth in the CaOH-capped pop-
ulation gain substantial effectiveness through root canal treatment. 
Analysis of the Cost Effectiveness Plane: In a lifecycle model, MTA pulp capping is 
more likely to give a comparative advantage for effectiveness than CaOH. The model 
shows that the initially higher cost of MTA treatment is offset by the lower post-MTA 
pulp capping cost. 
The following conclusions can be drawn: 
 According to this model, MTA pulp capping treatment should be the first 
treatment choice in the clinical situation of an open pulp if long-term-survival of 
a tooth is pursued. 
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4.6.2 Sensitivity Analysis (Hypothetical WTP) 
Decision uncertainty was analyzed by using cost-effectiveness acceptability curves. 
The figure below depicts the cost acceptability frontier along hypothetical WTP. The 
graph shows us which treatment alternative should be preferred under a given Willingness 
to Pay. Furthermore, the graph assigns a probability to a treatment option for being cost-
effective by using the variances that are included in the model from section 4.3 (clinical 
variances).  
 
 
Figure 17: Willingness To Pay: MTA Pulp Capping is Cost-Effective Under All Given 
Budgets 
 
When the treatment options are analyzed in a long-term scenario with an estimated sur-
vival of 48.8 years, along any given WTP, the strategy that is most likely cost-effective 
according to this model is MTA treatment. MTA had the highest likelihood of being 
cost-effective under any given WTP. Regardless of the assumed Willingness-to-Pay 
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ceiling value, MTA pulp capping has the highest probability of being cost-effective in 
this model. 
4.6.3 Extended Sensitivity Analysis (Probabilistic Sensitivity Analysis) 
Decisions are always based on imperfect information. One way of dealing with uncer-
tainty regarding cost and effectiveness is probabilistic sensitivity analysis (Robinson 
1993). Probabilistic SA allows testing the robustness of a model by varying the values 
and key variables to a certain extent and by checking the impact on the overall results. 
With probabilistic SA, the level of confidence in a model can be increased and areas 
where further research is needed can be identified (Weinstein and Stason 1977). Ranges 
and distributions are assigned to variables and a statistical tool is then used to select ran-
dom values for each range. Hereby, a large number of variables can be dealt with and a 
confidence interval can be calculated for each alternative.  
For this dissertation, probabilistic sensitivity analysis is intrinsic to the model for 
clinical effectiveness, since 95% confidence intervals were used for effectiveness 
values. Furthermore, the costs for MTA, CaOH and RCT were varied (10%); however, 
there was no impact on the outcome of the model. The probabilistic sensitivity analysis 
is depicted below. 
 
 
Figure 18: Monte Carlo Sampling of Variances (Effectiveness & Cost) 
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4.6.3.1 Extended CEA: Time-Dependent Analysis (Lifecycle Variation) 
As was shown above, MTA is effective in the long run. However, CaOH is less expensive 
than MTA and only slightly less effective in the short run. An in-depth analysis is added 
here, where time-horizon (lifecycle) is varied to see if cost effectiveness changes in a 
model for a tooth that has a shorter life span than the previous model of 48.8 years. 
It was necessary to find the life span of a tooth at which the choice between MTA and 
CaOH becomes indifferent. Why is this relevant for a decision maker? If a tooth has 
other conditions (that could influence its survival) in addition to open pulp, a life span 
can be defined at which it makes more sense to apply CaOH for cost saving. The model 
can thus inform a clinical decision maker until which estimated survival time it makes 
sense to apply CaOH and when it makes sense to apply the more expensive MTA, only 
taking health economics into account. 
 
 
Figure 19: Cost Effectiveness of Open Pulp Capping in a 5-Year Scenario 
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The graph above shows the cost effectiveness plane of a 5-year scenario. In this case, all 
treatment options are undominated. The analysis shows that MTA is slightly more ex-
pensive but achieves a significantly higher effectiveness than CaOH. It should also be 
noted that while MTA is only 2% more expensive than CaOH in this scenario, it is still 
21% more clinically effective. Furthermore, immediate RCT is also still a cost-effective 
treatment alternative in this model. However, while immediate RCT is 153% more ex-
pensive than MTA treatment, it is only 3% more clinically effective in this model. Fi-
nally, a cost-aware decision maker should choose CaOH as treatment alternative, and a 
clinical effectiveness-aware decision maker should choose immediate RCT as a treat-
ment alternative in this scenario. MTA should be chosen by an indifferent decision 
maker.  
 
In the next step, the cost effectiveness plane of a 6-year scenario is shown: 
 
 
Figure 20: Cost Effectiveness of Open Pulp Capping in a 6-Year Scenario 
 
55 
 
When the model is shifted from 5 to 6 years, MTA and RCT both dominate CaOH. CaoH 
is dominated in this model because it is more expensive and less clinically effective in 
this scenario. RCT is significantly more expensive and only slightly less clinically effec-
tive. When a decision maker should choose between MTA and RCT, the steep ICER 
should be considered.  
Therefore, the conclusion can be drawn from the previous two models that if remaining 
tooth life of a treated tooth is expected to be less than 6 years, CaOH treatment should be 
preferred by a cost-sensitive decision maker, since 6 years is the point in a time-dependent 
analysis at which CaOH becomes relatively more expensive than MTA and should there-
fore be avoided since resources could be used for something else. 
To conclude the extended time-dependent analysis, it can be stated from the models that 
for a tooth life expectancy of more than 6 years, a decision maker should opt for MTA as 
a treatment strategy. For a lifetime expectancy of 5 years or less, a decision maker should 
opt for CaOH as a treatment strategy for pulp capping.  
4.6.4 Overall Summary 
In a long-term lifecycle model, MTA pulp capping always has a head start in effectiveness 
compared to CaOH. The initially higher cost of MTA treatment is offset by the lower 
post-MTA cost for follow-up treatments. 
The following conclusions can be drawn as recommendations to a clinical decision maker 
based on the results of the models and extended analyses: 
 MTA pulp capping treatment should be the first treatment choice in the clini-
cal situation of an open pulp with a molar tooth when long-term survival of a tooth 
is pursued (48.55 years). 
 In a long-term model, under all budget conditions, MTA treatment should be the 
treatment of choice. 
 If expected life expectancy is varied, CaOH treatment is cost-efficient and 
should be preferred by a cost-sensitive decision maker from a 0 to 5-year sce-
nario. 
 If expected life expectancy is varied, MTA treatment is cost-efficient and should 
be preferred by a cost-sensitive decision maker in a 6-year scenario and above. 
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Modeling the cost and clinical outcome suggests that MTA pulp capping is more likely 
to be cost-effective in a lifetime scenario of 48.55 years in a German healthcare system 
setting. Therefore, the use of MTA as a pulp-capping material is clinically relevant and 
represents a cost-saving treatment strategy for treating an open pulp and when considering 
long-term economic consequences. 
The modeling results appear to be robust. The variance analysis shows that under different 
budget restrictions, MTA is cost-effective.  
 
4.7 Model Discussion  
 
A cost effectiveness analysis of open pulp treatment alternatives was performed based on 
latest available clinical evidence and a cost model based on GOZ and BEMA. One must 
now ask if all factors required for a good cost effectiveness analysis were fulfilled 
(Tonmukayakul et al. 2015). 
Factor 1 transparency of cost calculations: cost calculations were provided in de-
tail (see section 3.4). Thorough and transparent accounting for MTA treatment and 
alternative treatment options was demonstrated. 
Factor 2 cost discounting: 2% discounting was implemented into the model by us-
ing the discounting function in TreeAge Pro 2019. 
Factor 3 quality of underlying clinical endpoints: Mente’s underlying study de-
clared clinical endpoints. Full transparency was provided for clinical endpoints. How-
ever, for alternative treatment solutions, clinical endpoints were not researched in de-
tail. Further research of these clinical endpoints could improve the results of this study. 
It should be noted that the clinical data quality for this model was very high (e.g., time-
dependents phasing of survival curves was available). Therefore, high standards for cost-
effectiveness modeling and consecutive analysis were fulfilled. 
There might be certain limitations to this model that need to be discussed. CEA models 
can only be as good as their underlying data. It is possible that the lack of evidence in 
certain areas might have limited this cost effectiveness analysis. Some limitations of the 
models will be addressed. 
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First, it can be argued that cost-effectiveness information, i.e. information on cost 
and health resulting from the model, is a median average per individual for re-
spective treatment options within the Markov cohort. Within the TreeAge Pro 
2019 software, the individual treatment cost and health outcome for a treat-
ment/state is calculated by multiplying the health-gain/cost of a state with the 
likelihood that the state is reached. Therefore, decisions within this model are 
based on likelihood-adjusted medians – which is sufficient for decision making. 
However, outside of the model, the cost for a patient in the long run is never a likeli-
hood-adjusted median cost. Until the software provides functionality for Markov co-
horts to calculate cost on an individual level, this is the best information available as 
of today.  
Second, it can be argued from a clinical viewpoint that the clinical decision tree is 
missing root end surgery as a follow-up treatment option to root canal treatment. 
However, in practical dentistry root end surgery is mostly performed on single-rooted 
teeth and is barely performed on molar teeth due to the impeded accessibility of mul-
tiple roots in the maxilla bone (Ioannides and Borstlap 1983). Since the model is based 
on a molar tooth scenario, root end surgery was not included in the model.  
Third, it can be argued that the model and analysis were based on a single trial. 
However, a systematic review or meta-analysis of the clinical effectiveness of treat-
ments of an open pulp does not currently exist. Mente’s trial is a university setting 
trial and data was retrieved in only one country in one university setting. It is cur-
rently not known whether the treatment efficacy can be generalized across all patient 
and dentist populations. To further reduce uncertainty in the model and improve cost 
effectiveness analysis, enhanced clinical trials are needed and their data needs to be 
implemented into the models. However, as of today, and until further clinical studies 
are available, MTA as a therapeutic option for the treatment of an open pulp has the 
highest probability of being cost-effective in a long-term model and should therefore 
be chosen. 
The conclusion can be drawn that the model at hand, based on a single RCT for the 
clinical effectiveness of MTA vs. CaOH, indicated that decision making in favor of 
MTA in an open pulp scenario can be supported. However, in order to provide treat-
ment guidance (e.g. Leitlinie der Kassenzahnärztlichen Bundesvereinigung, the 
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guidelines of the German Public Dentists’ Association) to clinical decision makers, 
higher quality of evidence needs to be included in the model, e.g. systematic reviews or 
meta-analyses. Until further clinical studies are available, MTA has the highest likelihood 
of being cost-effective and should therefore be chosen in an open pulp treatment scenario. 
How the results of this dissertation can be implemented in clinical practice will be dis-
cussed in the overall discussion (see section 6.2) of this dissertation. 
The model presented here showed that high-quality clinical data can improve a model and 
enable sophisticated decision analysis. The next chapter will explore whether robust mod-
els can be built even if the underlying data is very limited. 
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5 Deciding on Cost-Effectiveness of Therapeutic 
Alternatives in the Emergency Situation of an 
Avulsed Tooth (Pulpal Trauma): Re-plantation vs. 
Implant-Supported Crown vs. Adhesive Bridge 
(Dry-time-dependent Comparative Scenario 
Analysis) 
 
5.1 Background Dental Trauma and Avulsed Tooth 
 
A dental trauma is defined as “an injury to the teeth and/or periodontium (gums, perio-
dontal ligament, alveolar bone), and nearby soft tissues such as the lips, tongue, etc.” 
(DentalTraumaGuide 2017). Most dental traumas happen to children with primary teeth 
within the age bracket of 2-3 years (Flores 2002) when children fall due to the movement 
system not being fully developed. In permanent teeth, most dental traumas occur due to 
falls/accidents, violence, sports or eating hard foods (Rocha and Cardoso 2001). 33% of 
adults have experienced trauma to their permanent dentition. Avulsions of permanent 
teeth happen in 0.5‐3% of all dental injuries (Glendor et al. 1996).  
Within dental trauma, tooth avulsion is a category of trauma that is defined as the 
complete displacement of a tooth from its socket in alveolar bone owing to trauma 
(Weber 2017). If avulsion occurs to a permanent tooth, immediate action is required by 
the dentist; the reaction time is of utmost importance. Avulsion is very painful and repre-
sents the most serious injury of all dental injuries (Andersson et al. 2012). The following 
section will explore which treatment options are available for a decision maker faced with 
an avulsed tooth. 
5.1.1 Avulsed Tooth and Re-plantation as a Treatment Option – a Medical 
Perspective 
If a patient is suffering from an avulsed tooth, different treatment options are available 
for a clinical decision maker in this model: re-plantation, implant with crown, and 
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adhesive bridge (for why conventional bridges are ruled out in this model, see section 
5.2.4). Whenever possible, re-plantation should be the first choice from a purely dental 
medical perspective and from a conservative dentistry perspective. 
 
 
 
Figure 21: Decision Tree Avulsed Tooth Treatment 
 
Since the focus of this dissertation is on pulpal disease/endodontics, special attention will 
be given to the re-plantation of an avulsed tooth. The remaining treatment options (im-
plant/crown, adhesive bridge) will only be briefly explained and assessed. Detailed eval-
uations of these approaches would be of interest in dissertations focusing on surgical or 
prosthetic aspects of dentistry. 
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5.1.2 Re-plantation Process and Guidelines 
When certain clinical requirements are met, re-plantation is the first treatment choice 
from a purely medical perspective in case of an avulsed permanent tooth. Guidelines for 
how the treatment should be performed by the dentist are issued by the International 
Association of Dental Traumatology (Keels and Section on Oral Health 2014):  
 Pre-clinical measures to be taken by patient or helpers: 
a. Pick tooth up by the crown; the root should not be touched 
b. Rinse tooth (10 sec); touching the root can result in cell crushing 
c. If replacement of the tooth is not possible, place the tooth in a storage 
medium, preferably “Dento Safe Box” 
d. Seek emergency dental treatment 
 Clinical measures to be taken by dentist: 
a. Inspect root surface carefully. Clean (rinse) root surface and carefully re-
move dead cells from root surface. Keep root surface moist. Avoid touch-
ing the root surface too much (avoid cell crushing) 
b. Pain management (local anesthesia) 
c. Examination of bone structure/alveolar socket (probing/X-ray) 
d. Prepare the socket for re-plantation  
e. Re-plant the tooth with slight pressure 
f. Verify normal position clinically and radiographically 
g. Apply a flexible splint 
h. Give patient instructions (soft food, etc.) 
i. Root canal treatment 7-10 days after re-plantation 
5.1.3 Anatomy of Re-plantation  
The medical principle underlying re-plantation is that the periodontal ligament that con-
nects the tooth to the bone is still healthy and can heal even though it has been severely 
damaged through avulsion. On the cell level, the periodontal ligament consists of con-
nective tissue cells (fibroblasts) that are located on the root’s surface. If a critical number 
of these cells remain vital and the cells are still attached to the tooth surface after avulsion, 
the avulsed tooth can be placed back in the alveolar pocket and re-generate. It is therefore 
crucial to keep the metabolism of fibroblasts going, so it must be ensured that the physi-
ological requirements are met while the tooth is outside the pocket in order to prevent the 
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fibroblasts from dying. The cells start dying 15 minutes after avulsion. The cells can be 
kept vital not only by keeping them wet, but also by providing them with a socket-like 
environment with regard to pH, osmolality and nutritional metabolites (e.g. glucose). 
There are special storage media (e.g. tooth safe boxes) that can significantly increase the 
success rate of a re-planted tooth.  The halves of the torn periodontal ligament fibers will 
re-connect when the tooth is re-planted. Touching the surface of an avulsed tooth there-
fore diminishes the clinical survival rate (Hargreaves and Louis H. Berman 2015). The 
main criterion that is used in a clinical situation for decision making in an avulsed tooth 
scenario is the dry-time of the tooth, which will be explained in the next section. 
5.2 Health Outcomes and Clinical Effectiveness of Avulsed 
Tooth Treatments 
5.2.1 Clinical Effectiveness of Re-Plantation 
It should be noted that the available data concerning the clinical effectiveness of re-
plantation of an avulsed tooth is limited. In 1995, Jens Andreasen published a prospec-
tive study on 400 human re-planted teeth (Andreasen et al. 1995) with follow-up peri-
ods of up to 20 years. In this clinical study, the significant correlation of dry time and 
healing complications was established. This study represents the highest available clin-
ical evidence for survival of re-planted tooth as of today. The study is a clinical non-
randomized controlled trial (non-RCT). This represents a low level in the evidence 
pyramid. However, Andreasen is an expert in dental trauma and is an active clinical 
researcher and publisher in this field (Andreasen et al. 2018). 
Even though the evidence level for clinical effectiveness is limited, the data will still 
be used for health economics modeling in this dissertation. Andreasen’s data is the 
best data available today. The latest systematic review on clinical effectiveness of re-
plantation, conducted by Nene and Bendgude in 2018, came to the conclusion (Nene and 
Bendgude 2018) that no publications contributing evidence to this field have been made 
since Andreasen’s study in 1995. Andreasen’s data is deemed to be appropriate for this 
chapter and for the research question of how a model can improve decision making in a 
situation where only limited clinical data is available.  
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5.2.2 Dry-time-dependent Scenarios for Clinical Effectiveness of Re-
Plantation 
The clinical success of re-plantation depends heavily on dry time (co-factor-dependent 
clinical effectiveness). There are 3 scenarios for the clinical effectiveness of re-planta-
tion of an avulsed tooth (Andreasen et al. 1995): 
1) Tooth out of alveolar pocket < 60 minutes and dry 
2) Tooth out of alveolar pocket 20-60 minutes and dry 
3) Tooth out of alveolar pocket > 60 minutes and dry 
The longer the tooth has been out of the pocket and dry, the more PDL cells have died, 
and survival is severely limited with increasing dry time (see section 4.2.2). 
The clinical data that will be used for the health economics modeling is: 
 
Co-factor: dry-time  
after tooth loss Failure rate (10 years) 95% Confidence interval [CI] 
0-20 min dry time 21.5% 6.5 – 36.5 
20-60 min dry time 44.4% 32.0 – 56.0 
>60 min dry time 70% 52.6 –87.6 
 
 
Figure 22: Dry-time-dependent Clinical Effectiveness of Re-Plantation (Andreasen, Bo-
rum et al. 1995) 
Since the clinical success of re-plantation of an avulsed tooth is highly dry-time-depend-
ent, the question arises whether the cost effectiveness changes depending on the dry-time 
of the avulsed tooth. Therefore, a comparative cost-effectiveness analysis will be per-
formed. 
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5.2.3 Alternative Treatments to Re-plantation 
5.2.3.1 Implant and Crown (Surgical Treatment Alternative) 
Whenever re-plantation of an avulsed tooth is not possible, an alternative treatment is 
placing an implant that will be provided with a prosthodontic crown as a supra-
construction after the alveolar socket is perfectly healed. Placing an implant with a 
prosthodontic crown is a well-accepted surgical/prosthodontic approach to replace a 
missing tooth. However, this approach is much more time-intensive than a conserva-
tive approach, more invasive, more stressful for the patient, and also significantly 
more expensive. 
5.2.3.2 Clinical Effectiveness of Implant and Crown 
A systematic review shows a 97% survival rate after 4 years (Creugers et al. 2000). 
Pjetursson (Pjetursson and Lang 2008), an acknowledged implant researcher, pub-
lished a median clinical survival rate of 94.5%, 95% CI: [91,8, 96.3] after 5 years 
for implant-supported reconstructions. 10-year survival rates are not available on 
a meta-analysis basis. However, a systematic review by Tomasi (Tomasi et al. 2008) 
shows that most studies also tend towards a 95% survival rate after 10 years. For 
modeling, 5-year survival rates will be extrapolated to 10-year survival rates with a 
slight discount, since most dental pathologies are progressive and not regressive.  
5.2.3.3 Adhesive Bridge (Prosthodontic Treatment Alternative) 
The second alternative approach to replace a missing tooth is an adhesive bridge. An 
adhesive bridge is a resin-bonded fixed partial denture that can be used to close a gap 
in the anterior region of the dental arch for permanent tooth replacement. The replaced 
prosthetic tooth is fixed with “wings” to the neighboring teeth and only minimal prep-
aration of the posterior side of the neighboring teeth is required (Prathyusha et al. 
2011). 
5.2.3.4 Clinical Effectiveness of Adhesive Bridge 
A systematic review of the  survival of adhesive bridges has been performed by Bal-
asubramaniam (Balasubramaniam 2017). Since survival is heavily dependent on re-
tentive preparation, the study that will be used for adhesive bridge survival is that 
conducted by Peter Rammelsberg (Pospiech et al. 1996; Rammelsberg et al. 1993). A 
survival rate of 95% for 10 years was found in the study; no variance was given. For 
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modeling, a 3% standard variance will be assumed, which results in a 10-year median 
clinical survival rate of 95% with 95% CI of [92.15%, 97.85%]. 
Another aspect that needs to be considered for modeling is that the most common 
complication is de-bonding, which happens in 19.2% of cases over 5 years. Therefore, 
the model adds 100 EUR for re-bonding in 19.2% of the cases after 5 years. 
5.2.4 Discarded Treatment Alternatives  
It needs to be mentioned here that a conventional bridge is also a treatment alterna-
tive for an avulsed tooth. However, in this case and model, it will be assumed that the 
neighboring teeth of the avulsed tooth are still in perfect condition. Treating a patient 
with a bridge requires invasive treatment of the neighboring teeth. Since the adhesive 
bridge is the superior prosthodontic treatment option when neighboring teeth are in 
good condition, the bridge as an alternative treatment approach is not a viable option 
here. 
Finally, it should be mentioned that the missing tooth could also be replaced with 
removable partial dentures. However, it can be argued that removable treatment 
solutions are not a comparable treatment alternative, since they are mostly used as 
temporary solutions before the permanent replacement of the missing tooth.  
5.3 Assumptions for Cost Effectiveness Modeling 
 
 All treatment happens within the context of the German healthcare system 
 Front tooth is fully avulsed 
 Tooth has one root canal 
 Male/female adult > 20 years 
 Apex of tooth is fully closed 
 Trauma guidelines of the International Association of Dental Traumatology are 
followed 
 Re-plantation: 2 weeks after re-plantation, RCT is successfully performed. Fol-
low-up treatment if re-plantation fails is adhesive bridge. 
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 Implant: Bone-grafting is not needed, enough bone available for implant. Imme-
diate prosthesis is made for adequate medical treatment after tooth loss and during 
implant process.  
 Adhesive bridge: 100 EUR added for re-attachment after 5 years (section 4.3.3.4) 
5.4 Cost Modeling of Avulsed Tooth Treatment 
 
Avulsed tooth treatment is accounted for as listed in the German fee scale for dentists 
(GOZ, see Bundesgesetzblatt 2001) and the German uniform fee scale for dental inter-
ventions (BEMA, see Bundesgesetzblatt 2001). Cost will be modeled analogously to the 
previous chapters; for further cost modeling details please refer to section 2.4. 
For this cost effectiveness analysis, a GOZ-only scenario will be drawn up because 
activities used in the model are not accounted for in BEMA. It was shown in Chapter 
2 that shifting from a publicly insured patient scenario to a privately insured patient sce-
nario only impacts a cost shift of all cost but does not change overall cost effectiveness. 
Therefore, costs of activities for the avulsed tooth treatment alternatives are calculated 
according to GOZ on the basis of the following formula (Bundesgesetzblatt 2001): 
Cost (GOZ, BEMA) = p (GOZ, BEMA)*µ*π 
 p (GOZ / BEMA) is the chargeable item points for a certain activity according to 
the GOZ / GEMA 
 µ is the monetary conversion factor (€ 051 per GOZ item point and € 0.95 accord-
ing to BEMA) 
 π is the treatment time factor, dependent on the complexity of the individual case” 
(π=1 in case of GOZ, π = 2.3 or 3.5 in case of BEMA) 
(Listl and Faggion 2010). 
 Cost evaluation of “Implant and crown” cost at 1,808.67 EUR was taken from 
(Schwendicke et al. 2014). Multiplier 2.3 was used for this calculation to assure 
comparability of treatment options, i.e. all treatment alternatives have been calcu-
lated using Multiplier 2.3 and GOZ accounting.  
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Taking all previous assumptions into account as well as the standard treatment process of 
an avulsed tooth explained in section 4.2.1, avulsed tooth treatment would be accounted 
for as shown in the following table by adding up the cost drivers for the different treat-
ment: 
 
 
 
Figure 23: Avulsed Tooth Treatment Cost according to GOZ 
  
Avulsed Tooth Treatment Privately insured – GOZ GOZ Points Amount Multiplier Cost
Re-Plantation Anamnesis & Consulting Ä1 100 1 2,3 12,94 €
Symptomspecific Diagnosis Ä5 100 1 2,3 12,94 €
X-Ray 5000 50 2 2,3 12,94 €
Local Anästhesia Upper jaw 90 60 1 2,3 7,76 €
Re-Plantation 3140 550 1 2,3 71,17 €
Stabilization 7070 90 2 2,3 23,29 €
Adhesive for Stabilization (per tooth) 2197 130 3 2,3 50,47 €
Extensive Post-OP Consulting 6190 140 1 2,3 18,12 €
Root Canal Treatment Trepanation 2390 65 1 2,3 8,41 €
VitEx ( per canal) 2360 110 1 2,3 14,23 €
Root Canal Treatment 1x 2410 392 1 2,3 50,72 €
Electromagnetic Legth Determination  (per canal and session)2400 70 1 2,3 9,06 €
Ultrasonic Rinsing (per canal) 2420 70 1 2,3 9,06 €
X-Ray 5000 50 3 2,3 19,41 €
Microscope 110 400 1 2,3 51,76 €
Root Canal Filling 2440 258 1 2,3 33,39 €
Adhesive Restoration F1 206 520 1 2,3 67,29 €
Removing adhesive stabilization 2702 300 1 2,3 38,82 €
Total 511,78 €
Adhesive Bridge Privately insured – GOZ GOZ Points Amount Multiplier Cost
Impregum 98a - 1 2,3 29,00 €
Adhesive Bridge Placement (NEM) 93b - 1 2,3 335,00 €
Abformung Lower Jaw 5170 250 1 2,3 32,34 €
Registration 8010 180 2 2,3 46,45 €
Arbitrary Scharnierachsenbestimmung 8020 300 1 2,3 38,80 €
Face Bow 8050 500 1 2,3 64,68 €
Dental Lab (Material & Time) 665,47 €
Total 1.211,74 €
Implant & Crown Privately insured – GOZ GOZ Points Amount Multiplier Cost
Total Implant/Crown cost according to Schwendicke (2014) 2,3 1.806,67 €
Total 1.806,67 €
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5.5 Markov Model (Transition State Model) 
 
A Markov state transition model (Sonnenberg and Beck 1993) was created using 
TreeAge Pro 2019 in order to enable CEA. The model was based on the clinical decision 
tree in section 4.2. 
 
 
 
 
 
 
 
 
 
The cost-effectiveness Plane shows the cost-effectiveness frontier for a Transition-State 
Model. In general, it can be said that the more to the right and the more to the bottom an 
alternative is located, the better is the respective cost-effectiveness. 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: State Transition Markov Model Re-plantation in TreeAge Pro 2019  
 
Avulsed 
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The model starts with the clinical situation of an avulsed tooth. In this situation, the 
clinical decision maker has the choice of 1) re-planting the tooth and continuing with 
root canal treatment; 2) skipping re-plantation and moving directly to placing an im-
plant with an implant-supported crown; 3) skipping re-plantation and moving directly to 
placing an adhesive bridge. From the state of an avulsed tooth, the re-planted tooth can 
transition into the post-re-plantation state, which occurs when re-plantation fails.  
Transition probabilities for a re-planted tooth were implemented into the model. For clin-
ical effectiveness, triangular distributions were implemented according to the 95% 
confidence interval. Cost was implemented according to GOZ calculations without any 
variance but will later be analyzed under variance analysis. The cycles in the transition 
state model represent a 10-year survival for all treatment alternatives, since reliable data 
for the 10-year horizon was available for all treatment options of an avulsed tooth.  
The Markov model was populated via Monte Carlo simulations (sample + trial) and a 
population of 10,000 teeth was created. The state transition model was implemented in 
TreeAge Pro 2019 as follows and additional analyses were run on the model. 
 
5.6 Deciding on Cost Effectiveness 
5.6.1 Cost Effectiveness Plane 
 
The cost effectiveness plane shows the cost effectiveness frontier for the state transition 
model based on cost and on 10-year survival of treatment alternatives for avulsed tooth 
treatment options. In general, it can be said that the more to the right and the lower an 
alternative is, the better is the respective cost-effectiveness. A comparative analysis was 
performed to analyze how cost effectiveness changes with different pre-requisites/exter-
nal factors (dry-time). 
  
  
 
 
Figure 25: (1) Scenario 1: Cost Effectiveness Plane +60 min dry time scenario; (2) Scenario 2: Cost Effectiveness Plane 20-60 min dry time sce-
nario; (3) Scenario 3: Cost Effectiveness Plane 0-20 min dry time scenario 
(2) Scenario 1 (20-60 min dry time) 1) Scenario 1 (+60 min dry time) (1) Scenario 3 (0-20 min dry time) 
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The cost effectiveness plane for the different dry time scenarios can be analyzed as fol-
lows (comparative analysis): 
  
 Scenario (1) +60 min dry time: Treatment option re-plantation is dominated by 
immediate adhesive bridge and by implant 
 Scenario (2) 20-60 min dry time: Re-plantation, immediate implant and imme-
diate adhesive bridge are all cost-effective treatment solutions within this sce-
nario. Extended variance analysis is recommended for the decision maker. 
 Scenario (3) 0-20 min dry time: Re-plantation, immediate implant and immedi-
ate adhesive bridge are all cost-effective treatment solutions within this scenario. 
Extended variance analysis is recommended for the decision maker. 
 
The following conclusions can be drawn from the comparative analysis as a recommen-
dation for the decision maker based on the 10-year model: 
 
 If an avulsed tooth has been out of the alveolar pocket for +60 minutes and 
stored dry, re-plantation as a first-time treatment option is dominated by implan-
tation and adhesive bridge in a 10-year scenario. Therefore, re-plantation is not 
cost-effective in this model. From a cost effectiveness perspective, immediate 
bridge or implant should be preferred.  
 If an avulsed tooth has been out of the alveolar pocket for 20-60 minutes and 
stored dry, re-plantation, immediate implant and adhesive bridge are all cost-ef-
fective treatment alternatives. However, re-plantation only slightly meets cost ef-
fectiveness criteria. If re-plantation was only slightly less effective or slightly 
more expensive, it would lose out on cost-effectiveness.  
Under variance analysis, re-plantation cost has a high standard deviation in the 
model, whereas implant and adhesive bridge do not have a deviation. Therefore, 
if the clinical advisor is risk-averse (or if there are other factors that could have a 
negative impact on the tooth) he should directly recommend implantation or ad-
hesive bridge. Since re-plantation and adhesive bridge have the same ICER, but 
adhesive bridge has a lower standard deviation with regard to cost and effective-
ness, adhesive bridge should be preferred from a health economics perspective in 
this model.  
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 If an avulsed tooth has been out of the alveolar pocket for 0-20 minutes and 
stored dry: re-plantation, immediate implant and immediate adhesive bridge are 
all cost-effective treatment solutions within this scenario. Comparing re-planta-
tion to adhesive bridge, the ICER of re-plantation is significantly less steep com-
pared with the ICER of immediate adhesive bridge and the ICER of the 20-60 min 
dry time scenario.  
The depicted cost effectiveness plane can be analyzed as follows (for details see 
appendix section 7.2): 
 
 In the 10-year model of an avulsed tooth, 8.3 life years can be 
gained for an average cost of 792.60 EUR with re-plantation and 
follow-up treatment. Effectiveness and cost both increase for re-
plantation and post-re-plantation treatments in the state transition 
model. It should be noted that these numbers are probability-ad-
justed medians. Variance analysis calculated with the Monte Carlo 
simulations shows that 97.5% of the values lie within the range of 
7.3 years to 9.1 years. 
 In the 10-year model of an avulsed tooth, 9.5 life years can be 
gained for an average cost of 1311 EUR by placing an adhesive 
bridge. The calculated ICER for adhesive bridge compared to re-
plantation is 432 EUR per additional life year. In percentages: a 
14.5% gain in clinical effectiveness can be gained for 65.4% more 
cost). 
 In the 10-year model of an avulsed tooth, 9.6 life years can be 
gained for an average cost of 1808 EUR by placing an implant. 
The calculated ICER for adhesive bridge compared to re-plantation 
is 781 EUR per additional life year. In percentages: 16.3% more 
clinical effectiveness can be gained for a 128.1% increase in cost). 
 
Looking at the variances and ICER, one can draw the conclusion that re-plantation of an 
avulsed tooth is preferable. If the decision maker has no budgetary constraints, more ef-
fective but more expensive treatment alternatives like immediate implant or immediate 
adhesive bridge should be considered. However, from a purely medical perspective, the 
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latter treatments have additional aspects that are not considered in the model (e.g. inva-
siveness of surgery) and should therefore be second choices. From a health economics 
perspective it makes sense for a decision maker to try re-plantation as a first-time 
treatment alternative.  
 
5.6.2 Sensitivity Analysis (Hypothetical WTP) 
Decision uncertainty was analyzed by using cost effectiveness acceptability curves. 
The figure below depicts the cost acceptability frontier along hypothetical WTP. The 
graph shows us which treatment alternative should be preferred under a given Willingness 
to Pay. Furthermore, the graph assigns a probability to a treatment option for being cost-
effective by using the variances that are included in the model from section 4.3.2 (clinical 
variances).  
 
 
Figure 26: Willingness to Pay Analysis of Avulsed Tooth Treatment Options 
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 An implant is the most cost-effective therapeutic choice given that the patient 
is willing to pay more than 880 EUR for the treatment of an avulsed tooth. 
 An adhesive bridge is the most cost-effective therapeutic choice given that 
the patient is willing to pay less than 880 EUR for the treatment of an avulsed 
tooth. 
5.6.3 Extended Sensitivity Analysis 
Probabilistic sensitivity analysis is intrinsic to the model for clinical effectiveness, since 
95% confidence intervals were used for effectiveness values. Furthermore, costs for treat-
ment alternatives were varied (10%); however, there was no impact on the outcome of 
the model. The probabilistic sensitivity analysis is depicted below. 
 
 
Figure 27: Monte Carlo Sampling of Variances for Avulsed Tooth Treatment Options 
(Effectiveness & Cost) 28: Monte Carlo Sampling of Variances for Avulsed Tooth 
Treatment Options (Effectiveness & Cost) 
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5.6.4 Overall Summary 
In a 10-year model, a comparative analysis shows that cost effectiveness of re-plantation 
is positively correlated with less dry time of an avulsed tooth: 
 In a +60 min dry time scenario, re-plantation is not cost-effective. Cost-effective 
treatment solutions are adhesive bridge and implant. 
 In a 20-60 min dry time scenario, re-plantation just meets cost effectiveness and, 
due to variances, can be recommended to a risk-taking decision maker. However, 
further in-depth analysis is needed to make further recommendations. Adhesive 
bridge and implant are also cost-effective, but with higher ICERs. 
 In a 0-20min dry time scenario, re-plantation is cost-effective. An in-depth anal-
ysis of the cost effectiveness plane and extended analysis of variances and Will-
ingness to Pay was performed.  
It was shown that cost effectiveness changes depending on the dry time of the avulsed 
tooth. In a 0-20 min dry time scenario, replantation should be preferred in the first place, 
with adhesive bridge and implant also being cost-effective. Under budgetary restrictions, 
a decision maker 1) willing to pay more than 880 EUR for the treatment of an avulsed 
tooth should decide for an implant, and one 2) not willing to pay more than 880 EUR for 
the treatment of an avulsed tooth should decide for an adhesive bridge. 
5.7 Model Discussion 
 
Based on the latest available clinical evidence and a cost model based GOZ, a cost-effec-
tiveness analysis of avulsed tooth treatment alternatives was performed. Overall, the 
model in this chapter was established in order to determine whether a model can be based 
on and be derived from a clinical decision scenario in which only very limited clinical 
information is available. This was the case for the clinical situation for the treatment of 
an avulsed tooth. Furthermore, the approach aimed at discovering “how far” a model can 
be taken that is based on rather experimental clinical information in the first place. Ulti-
mately, it was shown that even in cases of limited clinical information, data can be pro-
cessed in such a way that plausible trends in cost effectiveness can be identified. This was 
done by performing a comparative cost effectiveness analysis. 
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However, there is the question of whether all factors required for a good cost effectiveness 
analysis were fulfilled (Tonmukayakul et al. 2015). 
Factor 1 transparency of cost calculations: cost calculation was provided for in de-
tail (see section 4.5).  
Factor 2 cost discounting: 2% discounting was implemented into the model by us-
ing the discounting function in TreeAge Pro 2019. 
Factor 3 quality of underlying clinical endpoints: Andreasen’s underlying non-RCT 
on the clinical effectiveness of an avulsed tooth did not declare detailed information 
clinical endpoints. Neither were clinical endpoints of implant and adhesive bridge re-
searched in detail. However, the purpose and nature of this model was to demonstrate 
how modeling can overcome limited clinical information, and therefore the limited 
information on clinical endpoints was accepted. 
Furthermore, there might be certain limitations to this model that need to be discussed. 
First, a limitation of CEA is that a model can only be as good as its underlying data. 
The analysis was based on Andreasens’s non-RCT.  However, as of today, and until 
further clinical studies are available, the data provided by Andreasen for avulsed tooth 
treatment is the best data available. Further clinical data with higher-quality evidence 
(e.g. meta-analysis) of clinical effectiveness could further improve the results of this 
study. 
Second, due to limited clinical data, the model itself was kept simple. Due to a lack 
of survival curves in the underlying clinical data, no phasing of survival could be 
applied. The time horizon of the model was 10 years. In more sophisticated models, 
e.g. as in Chapter 3, time-dependent analyses could provide further insight into deci-
sion making. However, this was not possible in this case since long-term clinical data 
beyond 10 years was not available.   
Third, it may be argued that clinical effectiveness for adhesive bridge (95%) might 
be overstated in Rammelsberg’s study (Rammelsberg et al. 1993). However, it needs 
to be considered that the success rate of adhesive bridges in the study is based on the 
fulfillment of very specific design and treatment parameters for adhesive bridges. 
These are material selection (ceramics), preparation design (retentive preparation), 
and bonding requirement (roughening the tooth surface before adhesive bonding). An 
opposing argument can be made that many adhesive bridges fail in general practice 
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due to non-fulfillment of these very specific design and treatment parameters. Since 
all these parameters can be implemented by a dentist in general practice, it can be 
inferred that reaching clinical success rates for adhesive bridges is feasible.  
Fourth, it may be argued that an alternative to comparative dry-time-dependent 
scenario analysis could be to integrate dry time as a variable into the model and 
analyze cost effectiveness depending on dry time under variance analysis. How-
ever, this requires further research dealing with creating clinical effectiveness func-
tions that merge three dry-time-dependent probability functions into one meta-effec-
tiveness function in one model. If such a function was available, dry-time dependent 
analysis could be performed and a diagram could be drawn that depicts “likelihood of 
being cost effective” on the y-axis and “dry time” on the x-axis.  
To conclude, even though the clinical data was very limited and the evidence level of 
available clinical effectiveness was low, modeling and comparative cost effectiveness 
analysis revealed a trend in cost effectiveness (cost effectiveness is positively correlated 
to less dry time of an avulsed tooth) that can still be used to support decision making in 
this highly competitive environment of avulsed tooth treatment. Until further research is 
available, and within the limitations of this model, the likelihood is high that in a 0-20 
min dry time scenario, re-plantation is a cost-effective treatment alternative. 
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6 Concluding Part  
6.1 Summary of Results 
 
Within the possibilities and limitations of this dissertation in the field of dental health 
economics, the following three research questions were substantially explored: 
1. Which of the currently available treatment options for dentin hypersensitivity 
is the most cost-effective? The hypothesis is that there might be treatment alter-
natives that are more cost-effective than the gold standard treatment (chemical 
occlusion). 
2. There is evidence that MTA has a high clinical effectiveness when treating an 
open pulp. However, MTA is also more expensive than CaOH and treatment 
alternatives outside of pulp capping exist. The question then is which treatment 
option is cost-effective in the long run when cost and effectiveness of follow-up 
treatments are considered. The hypothesis is that application of transition state 
modeling enables long-term decision making.  
3. Is replantation of an avulsed tooth a cost-effective treatment alternative in 
case of dental trauma? The hypothesis is that a robust model can be built upon 
limited clinical data available and that variance analysis can be applied for as-
sessing the uncertainty of decision making. 
The results of the models can be summed up as follows: 
1. The Cost-effectiveness analysis compared physical occlusion, chemical oc-
clusion, nerve desensitization, laser and placebo for the treatment of dentin hy-
persensitivity. Physical occlusion was considered most cost-effective with an 
ICER of 7.76 EUR for the reduction of 1.0 units on the SMD pain scale (com-
pared with placebo). Both, chemical occlusion and nerve desensitization, were 
dominated. The ICER of laser was considered cost-intensive with 6.4 EUR for 
the additional reduction of 0.1 units on the SMD pain scale (compared with 
physical occlusion).  
2. The Cost-effectiveness analysis showed that MTA direct pulp capping treat-
ment has the highest likelihood of being cost-effective within the limitations of 
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the state transition model that was created to assess the long-term (48.55 years) 
effects of treatment alternatives in an open pulp situation. The ICER of MTA 
pulp capping was 403 EUR for 10.3 additional tooth life years (compared with 
no treatment). Both alternatives, CaOH direct pulp capping and Immediate 
RCT, were dominated.  
In situations, where expected tooth life is less than 6 years due to other reasons 
besides the open pulp, CaOH direct pulp capping should be preferred. 
3. The Cost-effectiveness analysis showed that in an avulsed tooth scenario re-
plantation has the highest likelihood of being cost-effective when dry time of 
the avulsed tooth is limited to 0-20 minutes. The ICER of re-plantation (com-
pared with no treatment) was 792.60 EUR for 8.3 additional tooth life years. 
Both alternatives, adhesive bridge and implant-supported crown, were not 
dominated, but were more cost-intensive. 
 
It was shown that opportunities exist to increase and improve health outcomes from 
a micro-economics perspective by re-allocating resources and treatments towards 
the right treatment alternative in the field of pulpal disease management (sections 
3.7, 4.6, 5.8). This can result in making better use of resources in the context of endo-
dontic treatment decision scenarios. Moreover, the need for continuous research into 
clinical effectiveness in endodontics was demonstrated (see section 3.13, 4.7, 5.7). 
The results revealed that EE techniques, i.e. CEA, can be applied to enable evidence-
based decision making in the field of dental health economics (section 5.1), thereby 
providing unbiased and transparent information about the value for money in the 
field of endodontics. Moreover, it was shown that patient-centeredness could be im-
plemented through decision analysis under a priori unknown budgetary constraints. 
Therefore, the challenges that were formulated in the introduction of this dissertation 
could be substantially addressed. 
The technical limitations of the models have been discussed in the respective chapter 
and can be found in sections 3.13, 4.7 and 5.9), but critical questioning of the overall 
impact of this dissertation will be addressed in the next section.  
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6.2 Discussion 
 
The main chapters of this dissertation have answered the research question through tech-
nical modeling of clinical situations in endodontics, upon which conclusions were drawn. 
The question that remains is what the implications of the results of this dissertation 
are for patients and dentists; this will be discussed in section 6.2.3. Furthermore, there 
might be possible limitations inherent to the CEA approach itself, which will be dis-
cussed in section 6.2.2. Also, there might be several limitations inherent to the method-
ical approach and modeling process of this dissertation, which will start off the discus-
sion. 
6.2.1 Challenges within the CEA Modeling Processes  
There were several challenges that came up during the process of applying CEA to the 
three research questions of this dissertation. The first challenge was to find appropriate 
clinical data for the effectiveness of the clinical situations derived from the research ques-
tions. Since the research questions covered multiple health states and treatments options, 
various sources of clinical data had to be accesses and evaluated. The next challenge was 
embedding these data sets into the modeling framework. It quickly became clear that three 
different research questions resulted in three heterogeneous data sets, and each of the 
research questions therefore required its own distinct model. While modeling was 
straightforward and standard for DHS treatment in chapter 2, the implementation of the 
long-term character in the open pulp in chapter 3 pushed the boundaries and a completely 
new model had to be implemented that included transition probabilities and health state 
(Markov models). As for the re-plantation in chapter 4, evidence was so scarce that com-
parative modeling was introduced, i.e. the model was built and run three times for three 
different dry time scenarios with the endeavor to perform a model comparison and a trend 
analysis was finally possible.  
Therefore, it can be stated that all data challenges could be overcome through enhanced 
statistical models and by creating highly individualized distinct models for each re-
search question that allowed dealing with the research questions of this dissertation.  
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6.2.2 Limitations of CEA as a method in EE 
Every methodology choice in health economics has its pros and cons (Drummond et 
al. 1993) and section 2.2 pointed out the reasons why CEA was chosen for this disserta-
tion. However, there might have been limitations intrinsic to CEA, which will be critically 
reviewed at this point, i.e. there might be limitations due to the fact that CEA was the 
methodological choice for this dissertation: 
 It can be argued that the ranking of alternatives might have limitations in CEA. 
Analyses might exist for which dominance may not be clear-cut and this might 
raise serious questions. In some cases, therapeutic options are ruled out due to 
being less effective and more expensive than a linear combination of two other 
therapeutic strategies, which is called extended dominance (Drummond 2001). 
If applied to a population, this can result in a mixed strategy for a population, 
which would leave part of a population with an inferior treatment choice 
(Cantor 1994), and ethical issues might be raised when a mixed strategy is ap-
plied. Taking the ethical issues of CEA a step further, it has been argued that it 
might be inappropriate or unethical to let cost influence clinical decision making 
due to CEA (Loewy 1980). In contrast, the majority of researchers remain neutral 
to the ethical discussion due to the fact that in health economics, cost should be 
rather seen as “opportunity cost”, i.e. what resources need to be given up for 
an alternative treatment (Williams 1992), which is also the viewpoint of the author 
of this dissertation. However, it should be acknowledged that analyses might exist 
that require deeper investigation of the ethical issues. 
 It can be argued that the introduction of ICER analysis into CEA – as also applied 
in this dissertation) raises several questions (Drummond 2001). ICER works in 
such a way that a choice is made when a threshold, i.e. hypothetical WTP, is lower 
than the ICER, which is the average cost per additional health outcome unit (see 
e.g. chapter 2 for DHS treatment). However, this implies the assumption of per-
fect divisibility of resources within the models. In real life however, resources 
or therapies are not perfectly divisible (e.g. if a root canal treatment costs 1000 
EUR and lasts 20 years, the patient cannot choose to pay only 500 EUR and main-
tain his tooth for just 10 years – therapeutic choices are mainly all or nothing). 
This limitation may have a significant impact on analyses and the risk has to be 
properly assessed. 
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 It can be argued that CEA analysis can only apply a one-dimensional primary 
endpoint for clinical effectiveness (Hanusch 2011). This limitation of CEA was 
also experienced in the modeling process of this dissertation. When different 
sources of clinical data for the models were aggregated, it was required that all 
clinical endpoints be the same or at least comparable, which can sometimes be 
difficult due to the fact that some clinical data from different resources do not 
reveal full details on clinical endpoints. However, this aspect could be managed 
within the models of this dissertation (e.g. by using the meta-endpoint-scales). It 
needs to be admitted that there might be modeling situations where clinical end-
points cannot be harmonized and further clinical research is needed with compa-
rable clinical endpoints.  
 It can be argued that patients’ preferences are only recognized by simulating budg-
ets in this dissertation and in CEA. However, personal preferences might exist 
beyond budgetary constraints (e.g. the hypothetical fact that “there might be pa-
tients who are indifferent to tooth loss and might assign zero value to an addi-
tional tooth life year” may not be accounted for in CEA models). Therefore, the 
implementation of extended preferences into the models might have a significant 
impact on the results of this dissertation. This could be solved by e.g. the intro-
duction of CBA or CUA. However, it needs to be noted that CEA was chosen due 
to the lack of evidence about patients’ preferences in endodontics (see section 
2.2). If this evidence was available, CBA and CUA could be introduced and eco-
nomic evaluation could be improved. Further research is needed in this regard so 
that patients’ preferences can be implemented into models on a higher level. 
 It can be argued that there are certain macroeconomic aspects that CEA cannot 
take into account (Drummond 2001). First, CEA cannot claim to take a sectoral 
view, which means where all possible interventions are compared in order to de-
cide on the right health care mix level. Therefore, CEA needs to be seen for what 
it was made for, namely to be used to compare several alternatives; it is used more 
for exploring decision making under budget restrictions. Second, CEA does not 
claim to deal with the whole wide range of decision making, taking all possible 
preventative, restorative, and prosthodontic possibilities into account that could 
benefit different groups of individuals differently. Third, CEA does not deal with 
finding the right health care mix on a very broad macro-economic level. However, 
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it can help to reveal that a current treatment is relatively cost-ineffective and iden-
tify some alternatives that are relatively cost-effective and that are not currently 
being fully utilized. But it can also be used as an indicator of where to investi-
gate into macro-economics and spark further research. CEA should be seen 
as a first indicator of where potential for resource reallocation exists with the goal 
of improving the total health level (WHO 2003). Fourth, CEA cannot quantify 
the final outcome and the full impact of decision making on the total healthcare 
system. However, the micro-economic results of this dissertation are a pivotal 
pre-requisite and the first step, i.e. a foundation for the macro-level assess-
ments as well as extended health policy assessments that take the “sectoral 
view”. Continuous research in public health on the macro-economic level of 
pulpal disease treatment can therefore significantly enhance the results of 
this dissertation.  
6.2.3 Limitations for Translation of Results into the Health Care System 
The previous sections evaluated the impact that CEA can have on the micro-economic 
level and explained that the results of this dissertation can be a first indicator for macro-
economic research. However, the question of what impact the results of this dissertation 
can have on the clinical decision maker level, i.e. the dentist, and what possible limitations 
exist for implementing the results into everyday clinical practice, remains. Therefore, I 
would like to direct the reader’s attention towards the debate around reasons or explica-
tion that hypothetically exist that could prevent clinical decision makers from implement-
ing results into day-to-day practice. 
6.2.3.1 Factors Impeding Translation of Knowledge into Clinical Practice from a 
Social Sciences Perspective (Behavioral View) 
The translation of research results beyond academia into everyday clinical practice is 
slow. Evidence exists that it takes about 17 years on average to implement the clinical 
results of an RCT into everyday clinical practice (IOM 2001). As long as new knowledge 
(e.g. as provided by the three models of this dissertation) is not translated into everyday 
clinical practice (micro-economic perspective), there will be no impact on the overall 
health output of a healthcare system (macro-economic perspective). 
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From a social sciences perspective (behavioral psychology), there are several reasons 
why the implementation of new knowledge into everyday clinical practice is slow. The 
social sciences, and in particular psychology, provide different theories that help ex-
plain the delay in translating knowledge into practice. Changing human behavior is not 
always easy. Habits are an essential part of human behavior and are defined as “behaviors 
that are performed automatically in a certain situation because they have been performed 
in the past” (Wood and Runger 2016). Individuals stick to habits because they know that 
at the end of a habit cycle there will be a certain reward. Therefore, it is very difficult for 
an individual to change habits since in many situations it is not clear what the reward will 
be for performing an alternative behavior (Verplanken 2018). 
One can apply habitual theory to clinical decision making in dentistry: dental treatments 
performed by a dental health decision maker can be compared to a habit. As an example, 
a dentist experiences the situation “open pulp” (certain situation) and automatically per-
forms the treatment “pulp capping with CaOH” as a habitual response to the situation. It 
is difficult for a dentist to break away from the habit cycle and instead treat an open 
pulp with MTA. Changing to MTA treatment involves a risk, and the reward is unclear, 
e.g., there is a risk that it will be more difficult and time-consuming to apply MTA com-
pared with CaOH. Another reason why decision makers stick to a treatment even though 
they “know” better is because evidence shows that an increase of information/knowledge 
does not necessarily change behavior, even when newly adopted intentions are strong 
(Walker et al. 2014).  
It can therefore be derived that the likelihood is high that dental health decision makers 
will stick to habitual treatment options, despite the evidence and knowledge about 
better treatment alternatives. The translation of knowledge into action can be hampered 
by the psychological factors just discussed.  
However, habit changes can be triggered by additional incentives, e.g. through “re-
wards”. From an economics perspective, the “reward” must be higher than the “cost” of 
changing the habit. Therefore, it becomes clear that providing information is necessary, 
but not necessarily sufficient to change habits within the dental health environment. The 
means through which healthcare systems can spark change at the micro-economic level 
are dealt with in the discipline of Public Health Economics. Further research on in-
centive systems in dental care is needed. 
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6.2.3.2 Evaluation of the Impact of this Dissertation on Ideal Health Output and 
Peak Performance of Health Systems 
The question of measuring the impact of the results of this dissertation on increasing the 
total dental health output still remains. A way of analyzing this would be to see what the 
characteristics of high performing health care systems are and whether the results of this 
dissertation can contribute to such characteristics.  
The Institute of Medicine (IOM) is a public US organization that is devoted to providing 
inputs on how to close the gap between the current and ideal state of a healthcare system. 
In 2009, the IOM published Crossing the Quality Chasm, a publication dealing with the 
question “How can a health care system better deal with translating knowledge into 
clinical practice” (Appendix 7.7). A comprehensive strategy is presented on how to re-
invent and improve the quality of care – with the ultimate goals of re-designing the whole 
healthcare system towards delivering high-quality care to patients and towards improv-
ing the overall health output of the healthcare system (IOM 2001).  
The starting points for re-designing the healthcare system are, first, creating supportive 
payment and regulatory environments, and second, facilitating patient-centered organiza-
tions in healthcare. The focus is then placed on re-designing the whole healthcare system 
and processes (e.g. re-engineering of care processes, increased use of IT in healthcare, 
coordination of processes and services, etc.). The IOM strategy defined six pivotal fac-
tors aimed at the improvement of healthcare systems: delivery of safe, effective, effi-
cient, personalized, timely and equitable health services to patients. It is argued that 
when major improvements are gained in all these factors, quality of care will appreciate, 
and the overall health output of the healthcare system will increase.  
Applying these factors and the IOM approach for knowledge translation into clinical prac-
tice to the results of this dissertation, the following IOM pivotal aims can be supported 
by the results of this dissertation. First, the results of this dissertation can contribute to 
the aim of delivering effective and efficient health services to patients in the field of 
pulpal disease treatment, as was explored in the CEAs in Chapters 3-5. Basically, CEA 
provides formal decision support in decision making situations, when a decision needs to 
be made between two or more alternatives. Second, the results of this dissertation can 
contribute to reaching the aim of delivering personalized health services to patients by 
creating evidence for decision making of a priori unknown budgetary restraints.  
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Therefore, the results of this dissertation can certainly contribute to the improvement of 
crucial two out of six IOM factors within the field of endodontics towards creating a 
high-performing health care system for pulpal disease management. 
6.3 Conclusion and Outlook 
 
Coming now to a final conclusion, several recommendations can be made based on 
the results and critical review of this dissertation. Continuous clinical research is 
needed in the area of pulpal disease treatment. The models presented in this dissertation 
can benefit from advanced systematic reviews/meta-analyses in the area of pulpal disease 
treatment. Once this data is available, models can be adjusted and advanced. It was also 
shown in this dissertation that creating economic evaluation models in dental health eco-
nomics is only a prerequisite for improving total health care systems and macro-
economic research is needed. The translation of knowledge of the results of cost effec-
tiveness analyses in the area of pulpal disease into implementation in everyday clinical 
practice and the re-design of a healthcare system towards patient-centered care is another 
challenging research area in public health that needs to be established for endodontics, 
i.e. pulpal disease treatment. As of today, cost effectiveness analysis will continue to be 
a very relevant tool for advancing the concept of patient-centered healthcare in the future, 
until more advanced evaluation prerequisites, e.g. monetary values for the benefits of 
endodontic treatments, become available for economic evaluation in dental healthcare. 
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To provide an outlook, a tentative roadmap for continuous research and progression of 
results towards translating dental health economic research into practice can be depicted 
as follows: 
 
The roadmap shows that CEA in endodontics is the very basic micro-economic founda-
tion that can ultimately lead towards improving quality of care and increasing the overall 
dental health output. It may be noted that even though the results of this dissertation might 
start out small, all things have to start somewhere.  
 
 
 
 
 
   
Figure 29: Roadmap for Continuous Health Economics Research in the Context of Pul-
pal Disease Treatment (own) 
Enabling patient-centered care 
Translating evidence/knowledge into clinical practice 
Enhancing models (e.g. CBA/CUA, long term modeling, etc.) 
Advancing clinical studies in pulpal disease management/endodontics 
CEA in the context of pulpal disease management– results of this dissertation 
Increased 
dental health 
output 
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“Knowing is not enough; we must apply. Willing is not enough; we must do”  
 
Johan Wolfgang von Goethe (1749-1832) 
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8 Appendix 
8.1 Cost & Effectiveness Variance Analysis for MTA vs. CaOH 
Treatment Options in an Open Pulp Scenario 
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8.2 Cost & Effectiveness Variance Analysis for Avulsed Tooth 
Treatment Options (0-20 min dry time)   
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8.3 Detailed Markov Transition State Model – MTA vs. CaOH 
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8.4 Detailed Markov Transition State Model – Avulsed Tooth 
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8.5 Cost & Effectiveness Variance Analysis for Avulsed Tooth 
Treatment Options 
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9 Summary (German) 
 
Heutzutage stehen bei der Entscheidungsfindung bezüglich Therapien bei Erkrankun-
gen der Zähne und des Zahnhalteapparats eine Vielzahl von Behandlungs-Alterna-
tiven zur Verfügung. Zumeist unterscheiden sich diese nicht nur in der klinischen Wirk-
samkeit, sondern auch hinsichtlich der Kosten. Im deutschen Gesundheitssystem sind 
viele zahnärztliche Leistungen mit Zusatzkosten für die Patienten verbunden - insbe-
sondere im Fachbereich der Endodontie. Hieraus resultiert die Anforderung, dass im kli-
nischen Alltag der Mehrwert der angebotenen Leistungen durch den Zahnarzt 
transparent kommuniziert wird. Ebenso gewinnen personalisierte Mundgesund-
heits-Strategien an Bedeutung, weshalb die Entscheidungsfindung zunehmend unter 
Berücksichtigung der individuellen Budget-Restriktionen der Patienten stattfindet. 
Diesen Anforderungen gerecht zu werden stellt bei der aktuellen Evidenz-Situation eine 
Herausforderung im klinischen Alltag dar. 
Ziel dieser Arbeit war es, gesundheitsökonomische Entscheidungs-Modelle herzulei-
ten, um die kosten-wirksamsten Therapie-Alternativen in verschiedenen klinisch re-
levanten Entscheidungsszenarien in der Endodontie zu identifizieren. Die Szenarien 
waren:  
1. Analyse von Therapie-Alternativen bei schmerzempfindlicher Reizung der 
Pulpa (Dentin-Überempfindlichkeit) 
2. Analyse von Therapie-Alternativen bei direkter Pulpa-Überkappung mit 
MTA vs. Calcium-Hydroxid bei Pulpa Aperta 
3. Zeit-Szenario-Analyse von Therapiealternativen im Falle eines avulsierten 
Zahnes (Pulpales Trauma) 
Einen geeigneten methodischen Untersuchungsrahmen stellte die gesundheitsökono-
mische Evaluation (Kosten-Wirksamkeit-Analysen) ausgehend von Entscheidungs-
baumanalysen und in Verbindung mit Markov-Chain-Monte-Carlo-Simulationen 
dar. Die Identifikation der kosten-wirksamsten Alternativen erfolgte durch Modellie-
rung der klinischen Entscheidungssituation auf Basis von 1) der aktuell verfügbaren Evi-
denz von klinischer Wirksamkeit und 2) der aktuell verfügbaren Kosten innerhalb des 
Kontexts des deutschen Gesundheitssystems. 
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Unter Berücksichtigung der Grenzen der Entscheidungsmodelle konnten folgende Er-
gebnisse erzielt werden:  
1. Der Vergleich der Kosten-Wirksamkeit von Physische Okklusion, Chemische 
Okklusion, Nerv-Desensibilisierung, Laser und Placebo zeigte, dass die Physische 
Okklusion die kosten-wirksamste Alternative bei der Behandlung der Dentin-Hy-
persensibilität ist. Der ICER von Physische Okklusion stellte sich (gegenüber 
Placebo) mit 7,76 EUR für die Reduktion von 1,0 Einheiten auf der SMD 
Schmerz-Skala dar. Sowohl Chemische Okklusion als auch Nerv-Desensibilisie-
rung wurden dominiert. Der ICER von Laser stellte sich (gegenüber physischer 
Okklusion) mit 6,4 EUR für die Reduktion von 0,1 Einheiten auf der SMD 
Schmerz-Skala als kostenintensive Alternative dar. 
2. Der Vergleich der Kosten-Wirksamkeit zeigte, dass die direkte Überkappung mit 
MTA bei Pulpa Aperta die kosten-wirksamste Behandlungsalternative in einem 
langfristigen Transition-State Modell ist. Die Alternativen Überkappung mit 
CaOH sowie Wurzelkanalbehandlung wurden dominiert. Der ICER von MTA 
stellte sich (gegenüber No-Treatment) mit Durchschnitts-Kosten von 403 EUR für 
10,3 Jahre Zahn-Überleben dar. Bei einem zu erwartenden Zahn-Überleben von 
unter 6 Jahren sollte aus gesundheitsökonomischer Sicht die Behandlung mit 
CaOH bevorzugt werden. 
3. Der Vergleich der Kosten-Wirksamkeit zeigte, dass die Re-plantation eines Zah-
nes die Kosten-wirksamste Behandlungsalternative darstellt, wenn der avulsierte 
Zahn einer extraoralen Trockenzeit von 0-20 Minuten ausgesetzt wurde. Der 
ICER von Re-plantation stellte sich (gegenüber No-Treatment) mit Durch-
schnitts-Kosten von 792,60 EUR für 8,3 Jahre Zahn-Überleben dar. Die Adhä-
siv-Brücke und Implantat-getragene Krone wurden nicht dominiert, stellten 
aber kostenintensivere Alternativen dar.  
Es wurde somit aufgezeigt, dass auf der Basis der aktuell verfügbaren Kosteninformation 
und klinischen Evidenz robuste Modelle zur Entscheidungsfindung im Fachbereich 
Endodontie der Zahnheilkunde erstellt werden konnten. Inwieweit die Ergebnisse dazu 
geeignet sind, eine Implementierung in den klinischen Behandlungsalltag zu ermög-
lichen, ist weiterhin zu klären. Hierzu werden zusätzliche Evidenz aus makro-ökono-
mischen Modellen und Public Health Studien sowie weitere klinische Studien für die En-
dodontologie benötigt.  
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10 Summary (English) 
 
When decisions are made for the treatment of dental diseases, different treatment op-
tions are available, which in most cases do not only differ in regard to clinical effective-
ness, but also in regard to cost. Within the context of the German health care system, 
many treatment options require co-pay from patients – especially in the field of endo-
dontics. Therefore, benefits of recommended treatments need to be transparently 
communicated by dentists to patients in everyday clinical practice. Furthermore, per-
sonalized oral health care strategies significantly gain importance, for which highly 
individual budget restrictions of patients need to be taken into account when treat-
ment decisions are made. Meeting these requirements is challenging for clinical de-
cisions makers with currently only limited evidence available. 
Goal of the dissertation was to develop different health economics decisions models for 
the identification of most cost-effective therapeutic alternatives for relevant and clini-
cally meaningful scenarios in endodontics, which were:  
1. Analysis of therapeutic alternatives for the treatment of painful irritation of the 
pulp (dentin hypersensitivity) 
2. Analysis of therapeutic alternatives for the treatment of an open pulp (MTA vs. 
CaOH - direct pulp capping) 
3. Time-Scenario-Analysis of therapeutic alternatives for the treatment of an avulsed 
tooth (pulpal trauma) 
A methodical framework that was used for conducting economic evaluations of the given 
scenarios was Cost-Effectiveness-Analysis. Scenarios were embedded through decision 
tree analyses in combination with Markov Models and Monte-Carlo Simulations. 
Models were detailed with 1) currently available clinical evidence for the effectiveness 
of treatments of teeth and the periodontal system in case of pulpal disease treatment, and 
2) available cost information within the context of the public and private German health 
care system. 
Within the given limitations of this dissertation, the results can be summed up as follows: 
1. The Cost-effectiveness analysis compared physical occlusion, chemical oc-
clusion, nerve desensitization, laser and placebo for the treatment of dentin 
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hypersensitivity. Physical occlusion was considered most cost-effective with an 
ICER of 7.76 EUR for the reduction of 1.0 units on the SMD pain scale (com-
pared with placebo). Both, chemical occlusion and nerve desensitization, were 
dominated. The ICER of laser was considered cost-intensive with 6.4 EUR for 
the additional reduction of 0.1 units on the SMD pain scale (compared with 
physical occlusion).  
2. The Cost-effectiveness analysis showed that MTA direct pulp capping treat-
ment has the highest likelihood of being cost-effective within the limitations of 
the state transition model that was created to assess the long-term (48.55 years) 
effects of treatment alternatives in an open pulp situation. The ICER of MTA 
pulp capping was 403 EUR for 10.3 additional tooth life years (compared with 
no treatment). Both alternatives, CaOH direct pulp capping and Immediate 
RCT, were dominated. In situations, where expected tooth life is less than 6 
years due to other reasons besides the open pulp, CaOH direct pulp capping 
should be preferred. 
3. The Cost-effectiveness analysis showed that in an avulsed tooth scenario re-
plantation has the highest likelihood of being cost-effective when dry time of 
the avulsed tooth is limited to 0-20 minutes. The ICER of re-plantation (com-
pared with no treatment) was 792.60 EUR for 8.3 additional tooth life years. 
Both alternatives, adhesive bridge and implant-supported crown, were not 
dominated, but were more cost-intensive. 
 
It was shown that robust economic models could be built based on currently available 
clinical evidence and cost information in the field of pulpal disease management. 
However, the results of this dissertation might be limited. Further research is needed 
for the assessment to which extent the results of this dissertation can be translated into 
everyday clinical practice. Therefore, additional evidence from macro-economic 
health models, public health studies and additional endodontic clinical evidence is 
required for further assessment of the models. 
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